US20050096316A1 - Quinoline derivatives(2) - Google Patents

Quinoline derivatives(2) Download PDF

Info

Publication number
US20050096316A1
US20050096316A1 US10/999,180 US99918004A US2005096316A1 US 20050096316 A1 US20050096316 A1 US 20050096316A1 US 99918004 A US99918004 A US 99918004A US 2005096316 A1 US2005096316 A1 US 2005096316A1
Authority
US
United States
Prior art keywords
mmol
alkyl
dissolved
calcd
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/999,180
Inventor
Carlo Farina
Giuseppe Giardina
Mario Grugni
Luca Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/en
Priority claimed from ITMI950494 external-priority patent/IT1293558B1/en
Application filed by Individual filed Critical Individual
Priority to US10/999,180 priority Critical patent/US20050096316A1/en
Publication of US20050096316A1 publication Critical patent/US20050096316A1/en
Priority to US11/385,461 priority patent/US7482458B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to novel quinoline derivatives, processes for their preparation and their use in medicine.
  • the mammalian peptide Neurokinin B belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA).
  • TK Tachykinin
  • SP Substance P
  • NKB Neurokinin A
  • NK 3 receptor antagonists are known (Drapeau, 1990 Regul. Pept., 31, 125-135), and findings with peptidic NK 3 receptor agonists suggest that NKB, by activating the NK 3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J. Phisiol., 470, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429; Mccarson and Krause, 1994, J. Neurosci., 14 (2), 712-720; Arenas et al. 1991, J. Neurosci., 11, 2332-8).
  • NK 3 antagonists which are far more stable from a metabolic point of view than the known peptidic NK 3 receptor antagonists and are of potential therapeutic utility in treating pulmonary disorders (asthma, chronic obstructive pulmonary diseases —COPD—, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, anxiety and psychosis). These disorders are referred to hereinafter as the Primary Disorders.
  • the novel NK 3 antagonists of the present invention are also of potential therapeutic utility in treating convulsive disorders (for example epilepsy), renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), psoriasis, Huntington's disease, and depression (hereinafter referred to as the Secondary Disorders).
  • convulsive disorders for example epilepsy
  • renal disorders urinary incontinence
  • ocular inflammation inflammatory pain
  • eating disorders food intake inhibition
  • allergic rhinitis for example Alzheimer's disease
  • neurodegenerative disorders for example Alzheimer's disease
  • psoriasis Huntington's disease
  • depression hereinafter referred to as the Secondary Disorders.
  • Ar examples of Ar are phenyl, optionally substituted by hydroxy, halogen, C 1-6 alkoxy or C 1-6 alkyl.
  • halogen examples of chlorine and fluorine, an example of C 1-6 alkoxy is methoxy and an example of C 1-6 alkyl is methyl.
  • Ar examples include thienyl and pyridyl.
  • Examples of Ar as a C 5-7 cycloalkdienyl group is cyclohexadienyl.
  • Example of R 1 and R 2 as C 1-6 alkyl is methyl; example of R 1 together with R forming a group-(CH 2 ) q — is spirocyclopentane.
  • R 3 and R 4 are methyl, ethyl, n-propyl, n-butyl, methoxy, hydroxy, amino, chlorine, fluorine, bromine, acetyloxy, 2-(dimetylamino)ethoxy, 2-(1-phthaloyl)ethoxy, aminoethoxy, 2-(1-pyn-olidinyl)ethoxy, phthaloyl, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino; dimethylaminomethyl and phenyl.
  • R 5 are cyclohexyl, phenyl optionally substituted as defined for Ar above; examples of R 5 as a heterocyclic group are furyl, thienyl, pyrryl, thiazolyl, benzofuryl and pyridyl.
  • a preferred group of compounds of formula (I) are those in which:
  • a further preferred group of compounds of formula (I) are those in which:
  • a particularly preferred group of compounds of formula (Ia) are those of formula (Ib) in which the group R is oriented downward and H upward.
  • the compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • a substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.
  • One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic.
  • Examples of pharmaceutically acceptable salts of a compound of formula (I) include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic, and methanesulphonic.
  • conventional pharmaceutical acids for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic, and methanesulphonic.
  • Examples of pharmaceutically acceptable solvates of a compound of formula (I) include hydrates.
  • the compounds of formula (I) may have at least one asymmetric centre and therefore may exist in more than one stereoisomeric form.
  • the invention extends to all such forms and to mixtures thereof, including racemates.
  • the invention also provides a process for the preparation of a compound of formula (I) which comprises reacting a compound of formula (III)
  • Suitable active derivatives of the compounds of formula (II) are acid halides (preferably chlorides), acid azides or acid anhydrides.
  • Another suitable derivative is a mixed anhydride formed between the acid and an alkyl chloroformate;
  • another suitable derivative is an activated ester such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p-nitrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-hydroxy-phtalimido ester, N-hydroxypiperidine ester, N-hydroxysuccinimide ester, N-hydroxy benzotriazole ester; or the carboxy group may be activated using a carbodiimide or N,N′-carbonyldiimidazole.
  • a compound of formula (Ic) may be converted to a compound of formula (I), or one compound of formula (I) may be converted to another compound of formula (I), by interconversion of suitable substituents.
  • certain compounds of formula (I) and (Ic) are useful intermediates in forming other compounds of the present invention.
  • R′ 2 may be hydrogen and converted to R 2 alkyl group, for example methyl, by conventional amide alkylation procedures (Zabicky, The chemistry of amides ; Interscience, London, 1970, p. 749).
  • X′ When X′ is oxygen, it may be converted to X sulphur by standard thioamide formation reagents, such as P 2 S 5 ( Chem Rev., 61, 45, 1961 or Angew. Chem, 78, 517, 1966) or the Lawesson reagent ( Tetrahedron, 41, 5061, 1985).
  • Ar′ or R′ 5 is a methoxy substituted phenyl
  • it may be converted to another Ar′ or R′ 5 hydroxy substituted phenyl by standard demethylation procedures via Lewis acids, such as boron tribromide (Synthesis, 249, 1983) or mineral acids, such as hydrobromic or hydroiodic acid.
  • Lewis acids such as boron tribromide (Synthesis, 249, 1983) or mineral acids, such as hydrobromic or hydroiodic acid.
  • R is an alkoxycarbonyl group, for example methoxycarbonyl
  • it may be converted to another R, such as ethoxycarbonyl by transesterification with an appropriate alcohol at a temperature in a range from 20 to 120° C., carboxy by hydrolysis in acidic or basic medium, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl by transamidation with ammonia, a primary amine or a secondary amine in methanol as solvent at a temperature in a range from 10 to 120° C., optionally in the presence of a catalytic amount of NaCN ( J. Org.
  • Scheme 2 summarizes some of the above described procedures to convert a compound of formula (Ic) or (I) in which X′ is oxygen, R′ is COOMe, Ar′ and R′ 1 to R′ 5 are as described for formula (I) to another compound of formula (I).
  • the compounds of formula (I) may be converted into their pharmaceutically acceptable acid addition salts by reaction with the appropriate organic or mineral acids.
  • Solvates of the compounds of formula (I) may be formed by crystallization or recrystallization from the appropriate solvent.
  • hydrates may be formed by crystallization or recrystallization from aqueous solutions, or solutions in organic solvents containing water.
  • salts or solvates of the compounds of formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the production of pharmaceutically acceptable salts or solvates. Accordingly such salts or solvates also form part of this invention.
  • the compounds of formula (I) may exist in more than one stereoisomeric form and the process of the invention may produce racemates as well as enantiomerically pure forms.
  • appropriate enantiomerically pure primary or secondary amines of formula (IIId) or (IIIe) are reacted with compounds of formula (II), to obtain compounds of formula (I′d) or (I′e).
  • Compounds of formula (II) are known compounds or can be prepared from known compounds by known methods.
  • the compound of formula (II), in which X′ is oxygen, R′ 3 , R′ 4 and R′ 5 are hydrogen is described in Pfitzinger, J. Prakt. Chem., 38, 582, 1882 and in Pfitzinger, J. Prakt. Chem., 56, 293, 1897;
  • the compound of formula (II), in which X′ is oxygen, R′ 3 and R′ 4 are hydrogen and R′ 5 is 2-pyridyl is described in Risaliti, Ric.
  • NK 3 receptor antagonists have potential therapeutic utility in treating the Secondary Disorders is new, and in a further aspect of the present invention there is provided the use of an NK 3 receptor antagonist for the treatment of the Secondary Disorders. There is also provided the use of an NK 3 receptor antagonist in the manufacture of a medicament for the treatment of any of the Secondary Disorders.
  • the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • the present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Disorders.
  • Such a medicament, and a composition of this invention may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring, agent, lubricant or preservative in conventional manner.
  • a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
  • the suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • the compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.
  • the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • compositions may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinyl-pyrrolidone
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
  • compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colour
  • compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • a pharmaceutically acceptable liquid e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the compounds of this invention may also be administered by inhalation, via the nasal or oral routes.
  • administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
  • Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles.
  • the compound particle size is from about 2 to 10 microns.
  • a further mode of administration of the compounds of the invention comprises transdermal delivery utilising a skin-patch formulation.
  • a preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient
  • pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.
  • the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration.
  • a unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • the composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg.
  • the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.
  • the present invention also provides a method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention further provides a method for the treatment and/or prophylaxis of the Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of an NK 3 receptor antagonist.
  • NK 3 ligands The activity of the compounds of the present invention, as NK 3 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK 3 ligands, [ 125 I]-[Me-Phe 7 ]-NKB or [ 3 H]-Senktide, to guinea-pig and human NK 3 receptors (Renzetti et al, 1991 , Neuropeptide, 18, 104-114; Buell et al, 1992 , FEBS, 299(1), 90-95; Chung et al, 1994 , Biochem. Biophys. Res. Commnn., 198(3), 967-972).
  • the NK 3 -antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990 , Br. J. Pharmacol., 101, 996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991 , Eur. J. Pharmacol., 199, 9-14) and human NK 3 receptors-mediated Ca++mobilization (Mochizuki et al, 1994 , J. Biol. Chem, 269, 9651-9658).
  • Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean K B value of 3-8 separate experiments, where K B is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide.
  • Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC 50 values) the Ca ++ mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.
  • the therapeutic potential of the compounds of the present invention in treating the conditions can be assessed using rodent disease models.
  • reaction mixture was evaporated in-vacuo to dryness, the residue was dissolved in EtOAc and washed twice with a sat. sol. of NaHCO 3 .
  • the organic layer was separated, dried over Na 2 SO 4 , filtered and evaporated in-vacuo to dryness.
  • DCC dicyclohexylcarbodiimide
  • the precipitated dicyclohexylurea was filtered off and the solution was evaporated in-vacuo to dryness.
  • the residue was dissolved in CH 2 Cl 2 and then washed with H 2 O.
  • the organic layer was separated, dried over Na 2 SO 4 and evaporated in-vacuo to dryness to obtain 6.0 g of a crude product which was dissolved in 20 ml of CH 2 Cl 2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • reaction mixture was evaporated in-vacuo to dryness and the residue was dissolved in EtOAc and washed twice with H 2 O. The organic layer was separated, dried over Na 2 SO 4 , filtered and evaporated in-vacuo to dryness.
  • the residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3:2 containing 0.5% NH 4 OH to afford 0.1 g of the crude product which was triturated with i—Pr 2 O to yield 0.08 g of the title compound.
  • reaction was quenched with 5 ml of H 2 O and extracted with CH 2 Cl 2 ; the organic layer was washed with H 2 O, 20% citric acid, saturated solution of NaHCO 3 and brine; the organic layer was separated, dried over Na 2 SO 4 and evaporated in vacuo to dryness.
  • the residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 70:30 containing 0.5% of conc. NH 4 OH to afford 0.64 g of a crude product which was triturated with warm i—Pr 2 O/1—PrOH 2:1, filtered, washed and dried to yield 0.5 g of the title compound.
  • the K 2 CO 3 was filtered off and the mixture was evaporated in vacuo to dryness, dissolved in AcOEt and washed with H 2 O and with 20% citric acid.
  • the aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na 2 SO 4 and evaporated in vacuo to dryness.
  • reaction mixture was then evaporated in vacuo to dryness and the residue dissolved in EtOAc; the solution was washed with water, saturated solution of NaHCO 3 , brine, dried over Na 2 SO 4 and evaporated in vacuo to dryness.
  • the crude product (0.39 g) was purified by silica gel flash column chromatography, eluting with a mixture of hexane/EtOAc/conc. NH 4 OH, 70:30:0.5, respectively, to afford 0.2 g of a pure compound which was recrystallized from acetone to yield 0.14 g of the title compound.
  • the K 2 CO 3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H 2 O and with 20% citric acid.
  • the aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na 2 SO 4 and evaporated in-vacuo to dryness.
  • the K 2 CO 3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in CH 2 Cl 2 and washed with H 2 O. The organic layer was dried over Na 2 SO 4 and evaporated in-vacuo to dryness.
  • reaction mixture was then evaporated in-vacuo to dryness, dissolved in 20 ml H 2 O, cooled and acidified with 10 ml conc. HCl.
  • the K 2 CO 3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H 2 O and 20% citric acid.
  • the aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na 2 SO 4 and evaporated in-vacuo to dryness.
  • reaction mixture was evaporated in-vacuo to dryness, suspended in 10 ml of CH 2 Cl 2 and dropped in 5 ml of ice-cooled 28% Me 2 NH/EtOH.
  • the precipitated TEA hydrochloride was filtered off and the filtrate concentrated in-vacuo to dryness; the residue was dissolved in CH 2 Cl 2 (100 ml) and washed with a sat. sol. of NaHCO 3 , 20% citric acid and brine. The organic solution was dried over Na 2 SO 4 and evaporated in-vacuo to dryness to obtain 13.23 g of an oil, which was crystallized from i—PrO2 (100 ml) containing 6 ml of i—PrOH to yield 9.14 g of the title compound as an off-white solid.
  • reaction mixture was evaporated in-vacuo to dryness, suspended in 100 ml of 33% Me 2 NH/EtOH and stirred overnight at room temperature.
  • the solution was evaporated in-vacuo to dryness, dissolved in 50 ml of 20% K 2 CO 3 and evaporated again in-vacuo to dryness. 50 ml of water were added to the residue and the solution, acidified with 37% HCl, was evaporated in-vacuo to dryness.
  • the precipitated dicyclohexylurea was filtered off and the organic layer evaporated in-vacuo to dryness.
  • I.R. (KBr): 3440; 3150; 3020; 2560; 2460; 1650; 1540 cm ⁇ 1 .
  • the precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness.
  • the residue was dissolved in CH 2 Cl 2 and washed with H 2 O, sat. sol. NaHCO 3 , 5% citric acid, sat. sol. NaHCO 3 and brine.
  • the precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness.
  • the residue was dissolved in CH 2 Cl 2 and washed with H 2 O, sat. sol. NaHCO 3 , 5% citric acid, sat. sol. NaHCO 3 and brine.

Abstract

NK3 receptor antagonists of formula (I):
Figure US20050096316A1-20050505-C00001
 are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.

Description

  • The present invention relates to novel quinoline derivatives, processes for their preparation and their use in medicine.
  • The mammalian peptide Neurokinin B (NKB) belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA). Pharmacological and molecular biological evidence has shown the existence of three subtypes of TK receptor (NK1, NK2 and NK3) and NKB binds preferentially to the NK3 receptor although it also recognises the other two receptors with lower affinity (Maggi et al, 1993, J. Auton. Pharmacol., 13, 23-93).
  • Selective peptidic NK3 receptor antagonists are known (Drapeau, 1990 Regul. Pept., 31, 125-135), and findings with peptidic NK3 receptor agonists suggest that NKB, by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J. Phisiol., 470, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429; Mccarson and Krause, 1994, J. Neurosci., 14 (2), 712-720; Arenas et al. 1991, J. Neurosci., 11, 2332-8).
  • However, the peptide-like nature of the known antagonists makes them likely to be too labile from a metabolic point of view to serve as practical therapeutic agents.
  • We have now discovered a novel class of selective, non-peptide NK3 antagonists which are far more stable from a metabolic point of view than the known peptidic NK3 receptor antagonists and are of potential therapeutic utility in treating pulmonary disorders (asthma, chronic obstructive pulmonary diseases —COPD—, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, anxiety and psychosis). These disorders are referred to hereinafter as the Primary Disorders.
  • The novel NK3 antagonists of the present invention are also of potential therapeutic utility in treating convulsive disorders (for example epilepsy), renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), psoriasis, Huntington's disease, and depression (hereinafter referred to as the Secondary Disorders).
  • According to the present invention there is provided a compound, or a solvate or salt thereof, of formula (I):
    Figure US20050096316A1-20050505-C00002
    in which:
    • Ar is an optionally substituted phenyl, naphthyl or C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
    • R is linear or branched C1-8 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatom selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxyxcarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or is a group —(CH2)p— when cyclized onto Ar, where p is 2 or 3.
    • R1 and R2, which may be the same or different, are independently hydrogen or C1-6 linear or branched alkyl, or together form a —(CH2)n— group in which n represents 3, 4, or 5; or R1 together with R forms a group —(CH2)q—, in which q is 2, 3, 4 or 5.
    • R3 and R4, which may be the same or different, are independently hydrogen, C1-6 linear or branched alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C1-6 alkylamino, —O(CH2)r—NT2, in which r is 2, 3, or 4 and T is hydrogen or C1-6 alkyl or it forms with the adjacent nitrogen a group
      Figure US20050096316A1-20050505-C00003
      in which V and V1 are independently hydrogen or oxygen and u is 0, 1 or 2; —O(CH2)S—OW2 in which s is 2, 3, or 4 and W is hydrogen or C1-6 alkyl; hydroxyalkyl, aminoalkyl, mono-or di-alkylaminoalkyl, acylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group —(CH2)t— when cyclized onto R5 as aryl, in which t is 1, 2, or 3;
    • R5 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
    • X is O, S, or N—C≡N.
  • Examples of Ar are phenyl, optionally substituted by hydroxy, halogen, C1-6 alkoxy or C1-6 alkyl. Examples of halogen are chlorine and fluorine, an example of C1-6 alkoxy is methoxy and an example of C1-6 alkyl is methyl.
  • Examples of Ar as a heterocyclic group are thienyl and pyridyl.
  • Examples of Ar as a C5-7 cycloalkdienyl group is cyclohexadienyl.
  • Examples of R are as follows:
    • C1-8 alkyl: methyl, ethyl, n-propyl, iso-propyl, n-butyl, heptyl; phenyl C1-6 alkyl: benzyl;
    • hydroxy C1-6 alkyl: —CH2OH, —CH2CH2OH, CH(Me)OH; amino C1-6 alkyl: —CH2NH2;
    • di C1-6 alkylaminoalkyl: —CH2NMe2;
    • C1-6 alkoxylalkyl: CH2OMe;
    • C1-6 alkylcarbonyl: COMe;
    • C1-6 alkoxycarbonyl: COOMe;
    • C1-6 alkoxycarbonyl C1-6 alkyl: CH2COOMe;
    • C1-6 alkylaminocarbonyl: CONHMe;
    • di C1-6 alkylaminocarbonyl: CONMe2, CO(1-pyrrolidinyl);
    • halogen C1-6 alkyl: trifluoromethyl;
    • —(CH2)p— when cyclized onto Ar:
      Figure US20050096316A1-20050505-C00004
  • Example of R1 and R2 as C1-6 alkyl is methyl; example of R1 together with R forming a group-(CH2)q— is spirocyclopentane.
  • Examples of R3 and R4 are methyl, ethyl, n-propyl, n-butyl, methoxy, hydroxy, amino, chlorine, fluorine, bromine, acetyloxy, 2-(dimetylamino)ethoxy, 2-(1-phthaloyl)ethoxy, aminoethoxy, 2-(1-pyn-olidinyl)ethoxy, phthaloyl, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino; dimethylaminomethyl and phenyl.
  • Examples of R5 are cyclohexyl, phenyl optionally substituted as defined for Ar above; examples of R5 as a heterocyclic group are furyl, thienyl, pyrryl, thiazolyl, benzofuryl and pyridyl.
  • A preferred group of compounds of formula (I) are those in which:
      • Ar is phenyl, optionally substituted by C1-6 alkyl or halogen; thienyl or a C5-7 cycloalkdienyl group;
      • R is C1-6 alkyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyl, hydroxy C1-6 alkyl;
      • R1 and R2 are each hydrogen or C1-6 alkyl;
      • R3 is hydrogen, hydroxy, halogen, C1-6 alkoxy, C1-6 alkyl;
      • R4 is hydrogen, C1-6 alkyl, C1-6 alkoxy, hydroxy, amino, halogen, aminoalkoxy, mono- or di-alkylaminoalkoxy, mono- or di-alkylaminoalkyl, phthaloylalkoxy, mono- or di-alkylaminoacylamino and acylamino;
      • R5 is phenyl, thienyl, furyl, pyrryl and thiazolyl.
  • A further preferred group of compounds of formula (I) are those in which:
      • Ar is phenyl, 2-chlorophenyl, 2-thienyl or cyclohexadienyl;
      • R is methyl, ethyl, n-propyl, —COOMe, —COMe;
      • R1 and R2 are each hydrogen or methyl;
      • R3 is hydrogen, methoxy, or hydroxy;
      • R4 is hydrogen, methyl, ethyl, methoxy, hydroxy, amino, chlorine, bromine, dimethylaminoethoxy, 2-(1-phthaloyl)ethoxy, aminoethoxy, 2-(1-pyrrolidinyl)ethoxy, dimethylamrinopropoxy, dimethylaminoacetylamino, acetylamino, and dimethylaminomethyl.
      • R5 is phenyl, 2-thienyl, 2-furyl, 2-pyrryl, 2-thiazolyl and 3-thienyl;
      • and X is oxygen.
  • A preferred sub-group of compounds within the scope of formula (I) above is of formula (Ia):
    Figure US20050096316A1-20050505-C00005
    in which:
      • R, R2, R3 and R4 are as defined in formula (I), and Y and Z, which may be the same or different, are each Ar as defined in formula (I).
  • A particularly preferred group of compounds of formula (Ia) are those of formula (Ib) in which the group R is oriented downward and H upward.
    Figure US20050096316A1-20050505-C00006
  • The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate. One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic.
  • Examples of pharmaceutically acceptable salts of a compound of formula (I) include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic, and methanesulphonic.
  • Examples of pharmaceutically acceptable solvates of a compound of formula (I) include hydrates.
  • The compounds of formula (I) may have at least one asymmetric centre and therefore may exist in more than one stereoisomeric form. The invention extends to all such forms and to mixtures thereof, including racemates.
  • The invention also provides a process for the preparation of a compound of formula (I) which comprises reacting a compound of formula (III)
    Figure US20050096316A1-20050505-C00007
      • in which R′, R′1, R12 and Ar′ are R, R1, R2 and Ar as defined for formula (I) or a group or atom convertible to R, R1, R2 and Ar, with a compound of formula (II)
        Figure US20050096316A1-20050505-C00008
      • or an active derivative thereof, in which R′3, R′4, R′5 and X′ are R3, R4, R5 and X as defined for formula (I) or a group convertible to R3, R4, R5 and X, to form a compound of formula (Ic)
        Figure US20050096316A1-20050505-C00009
      • and optionally thereafter performing one or more of the following steps:
      • (a) where R′, R′1 to R′5, Ar′ and X′ are other than R, R1 to R5, Ar and X, converting any one of R′, R′1 to R′5, Ar′ and X′ to R, R1 to R5, Ar and X to obtain a compound of formula (I),
      • (b) where R′, R′1 to R′5, Ar′ and X′ are R, R1 to R5, Ar and X, converting any one of R, R1 to R5, Ar and X to another R, R1 to R5, Ar and X, to obtain a compound of formula (I),
      • (c) forming a salt and/or solvate of the obtained compound of formula (Ic).
  • Suitable active derivatives of the compounds of formula (II) are acid halides (preferably chlorides), acid azides or acid anhydrides. Another suitable derivative is a mixed anhydride formed between the acid and an alkyl chloroformate; another suitable derivative is an activated ester such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p-nitrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-hydroxy-phtalimido ester, N-hydroxypiperidine ester, N-hydroxysuccinimide ester, N-hydroxy benzotriazole ester; or the carboxy group may be activated using a carbodiimide or N,N′-carbonyldiimidazole.
  • For example, in standard methods well known to those skilled in the art, the compounds of formula (III) may be coupled:
      • (a) with an acid chloride in the presence of an inorganic or organic base in a suitable aprotic solvent such as dimethylformamide (DMF) at a temperature in a range from −70 to 50° C. (preferably in a range from −10 to 20° C.),
      • (b) with the acid in the presence of a suitable condensing agent, such as for example N,N′-carbonyl diimidazole (CDI) or a carbodiimide such as dicyclohexylcarbodiimide (DCC) or N-dimethylaminopropyl-N′-ethylcarbodiimide and N-hydroxybenzotriazole (HOBT) to maximise yields and avoid racemization processes (Synthesis, 453, 1972) in an aprotic solvent such as a mixture of acetonitrile (MeCN) and tetrahydrofuran (THF) in a ratio from 1:9 to 7:3, respectively, at a temperature in a range from −70 to 50° C. (preferably in a range from −10 to 25° C.) (see Scheme 1),
        Figure US20050096316A1-20050505-C00010
      • (c) with a mixed anhydride generated in situ from the acid and an alkyl (for example isopropyl) chloroformate in a suitable aprotic solvent such as dichloromethane at a temperature in a range from −70 to 50° C. (preferably in a range from −20 to 20° C.).
  • It will be appreciated that a compound of formula (Ic) may be converted to a compound of formula (I), or one compound of formula (I) may be converted to another compound of formula (I), by interconversion of suitable substituents. Thus, certain compounds of formula (I) and (Ic) are useful intermediates in forming other compounds of the present invention.
  • For example R′2 may be hydrogen and converted to R2 alkyl group, for example methyl, by conventional amide alkylation procedures (Zabicky, The chemistry of amides; Interscience, London, 1970, p. 749). When X′ is oxygen, it may be converted to X sulphur by standard thioamide formation reagents, such as P2S5 (Chem Rev., 61, 45, 1961 or Angew. Chem, 78, 517, 1966) or the Lawesson reagent (Tetrahedron, 41, 5061, 1985). When Ar′ or R′5 is a methoxy substituted phenyl, it may be converted to another Ar′ or R′5 hydroxy substituted phenyl by standard demethylation procedures via Lewis acids, such as boron tribromide (Synthesis, 249, 1983) or mineral acids, such as hydrobromic or hydroiodic acid. When R is an alkoxycarbonyl group, for example methoxycarbonyl, it may be converted to another R, such as ethoxycarbonyl by transesterification with an appropriate alcohol at a temperature in a range from 20 to 120° C., carboxy by hydrolysis in acidic or basic medium, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl by transamidation with ammonia, a primary amine or a secondary amine in methanol as solvent at a temperature in a range from 10 to 120° C., optionally in the presence of a catalytic amount of NaCN (J. Org. Chem., 52, 2033, 1987) or by using trimethylaluminium (Me3Al) (Tetrahedron Letters, 48, 4171, 1977), hydroxymethyl by a selective metal hydride reduction, such as lithium borohydride reduction (Tetrahedron, 35, 567, 1979) or sodium borohydride reduction in THF+MeOH (Bull. Chem Soc. Japan, 57, 1948, 1984 or Synth. Commun., 12, 463, 1982), alkylcarbonyl by acyl chloride formation and subsequent reaction with alkylmagnesium halides in THF as solvent at a temperature in a range from −78 to 30° C. (Tetrahedron Letters, 4303, 1979) or with alkylcadmium halides or dialkylcadmium in the presence of MgCl2 or LiCl (J. Org. Chem, 47, 2590, 1982). Another group which R′ as methoxycarbonyl can be converted into is a substituted heteroaromatic ring, such as an oxadiazole (J. Med. Chem, 34, 2726, 1991).
  • Scheme 2 summarizes some of the above described procedures to convert a compound of formula (Ic) or (I) in which X′ is oxygen, R′ is COOMe, Ar′ and R′1 to R′5 are as described for formula (I) to another compound of formula (I).
    Figure US20050096316A1-20050505-C00011
  • The compounds of formula (I) may be converted into their pharmaceutically acceptable acid addition salts by reaction with the appropriate organic or mineral acids.
  • Solvates of the compounds of formula (I) may be formed by crystallization or recrystallization from the appropriate solvent. For example, hydrates may be formed by crystallization or recrystallization from aqueous solutions, or solutions in organic solvents containing water.
  • Also salts or solvates of the compounds of formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the production of pharmaceutically acceptable salts or solvates. Accordingly such salts or solvates also form part of this invention.
  • As mentioned before, the compounds of formula (I) may exist in more than one stereoisomeric form and the process of the invention may produce racemates as well as enantiomerically pure forms. To obtain pure enantiomers, appropriate enantiomerically pure primary or secondary amines of formula (IIId) or (IIIe)
    Figure US20050096316A1-20050505-C00012
    are reacted with compounds of formula (II), to obtain compounds of formula (I′d) or (I′e).
    Figure US20050096316A1-20050505-C00013
  • Compounds of formula (I′d) or (I′e) may subsequently be converted to compounds of formula (Id) or (Ie) by the methods of conversion mentioned before.
    Figure US20050096316A1-20050505-C00014
  • Compounds of formula (II) are known compounds or can be prepared from known compounds by known methods.
  • For example, the compound of formula (II), in which X′ is oxygen, R′3, R′4 and R′5 are hydrogen is described in Pfitzinger, J. Prakt. Chem., 38, 582, 1882 and in Pfitzinger, J. Prakt. Chem., 56, 293, 1897; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is 2-pyridyl is described in Risaliti, Ric. Scient., 28, 561, 1958; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is o-, m- and p-chlorophenyl, o-fluorophenyl and 3,4-dichlorophenyl are described in Brown et al., J. Am. Chem. Soc., 68, 2705, 1946; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is p-methoxyphenyl is described in Ciusa and Luzzatto, Gazz. Chim. Ital., 44, 64, 1914; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is m-trifluoromethylphenyl is described in Shargier and Lalezari, J. Chem. Eng. Data, 8, 276, 1963; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is p-fluorophenyl is described in Bu Hoi et al., Rec Trav. Chim., 68, 781, 1949; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is p-methylphenyl is described in Prevost et al., Compt. Rend. Acad. Sci., 258, 954, 1964; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is p-bromophenyl is described in Nicolai et al., Eur. J. Med. Chem, 27, 977, 1992; the compound of formula (II) in which X′ is oxygen, R′4 and R′5 are hydrogen and R′3 is 6-methyl is described in Buchmann and Howton, J. Am. Chem. Soc., 68, 2718, 1946; the compound of formula (II), in which X′ is oxygen, R′4 and R′5 are hydrogen and R′3 is 8-nitro is described in Buchmann et al, J. Am. Chem. Soc., 69, 380, 1947; the compound of formula (II), in which X′ is oxygen, R′4 is hydrogen, R′3 is 6-chloro, R′5 is p-chlorophenyl is described in Lutz et al., J. Am. Chem Soc., 68, 1813, 1946; the compound of formula (II), in which X′ is oxygen, R′3 and R′4 are hydrogen and R′5 is 2-thiazolyl is described in Eur. Pat. Appl. EP 112,776; compounds of formula (II), in which X′ is oxygen, R′3 is 8-trifluoromethyl, R′4 is hydrogen and R′5 are phenyl, o- and p-fluorophenyl, 3,4-dichlorophenyl, p-methoxyphenyl are described in Nicolai et al., Eur. J. Med. Chem., 27, 977, 1992; compounds of formula (II), in which X′ is oxygen, R′3 is 6-bromo, R′4 is hydrogen and R′5 are phenyl or p-fluorophenyl are described in Nicolai et al., Eur. J. Med. Chem., 27, 977, 1992; other compounds of formula (II) are described in Ger. Offen. DE 3,721,222 and in Eur. Pat. Appl. EP 384,313.
  • Compounds of formula (III), (IIId) and (IIIe) are commercially available compounds or can be prepared from known compounds by known methods (for example, compounds of formula (III) in which R′ is alkoxycarbonyl, R′1 and R′2 are hydrogen and Ar′ is as defined for the compounds of formula (I), are described in Liebigs Ann. der Chemie, 523, 199, 1936).
  • The activity of the compounds of formula (I) as NK3 receptor antagonists in standard tests indicates that they are of potential therapeutic utility in the treatment of both the Primary and Secondary Disorders herein before referred to.
  • The discovery that NK3 receptor antagonists have potential therapeutic utility in treating the Secondary Disorders is new, and in a further aspect of the present invention there is provided the use of an NK3 receptor antagonist for the treatment of the Secondary Disorders. There is also provided the use of an NK3 receptor antagonist in the manufacture of a medicament for the treatment of any of the Secondary Disorders.
  • The present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.
  • The present invention further provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Disorders.
  • Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring, agent, lubricant or preservative in conventional manner.
  • These conventional excipients may be employed for example as in the preparation of compositions of known agents for treating the conditions.
  • Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
  • The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
  • Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • The compounds of this invention may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • The compounds of this invention may also be administered by inhalation, via the nasal or oral routes. Such administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
  • Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles. Preferably, the compound particle size is from about 2 to 10 microns.
  • A further mode of administration of the compounds of the invention comprises transdermal delivery utilising a skin-patch formulation. A preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient For a constant rate of percutaneous absorption, pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.
  • As mentioned above, the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg. The composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.
  • No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention.
  • The present invention also provides a method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • The invention further provides a method for the treatment and/or prophylaxis of the Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of an NK3 receptor antagonist.
  • The activity of the compounds of the present invention, as NK3 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK3 ligands, [125I]-[Me-Phe7]-NKB or [3H]-Senktide, to guinea-pig and human NK3 receptors (Renzetti et al, 1991, Neuropeptide, 18, 104-114; Buell et al, 1992, FEBS, 299(1), 90-95; Chung et al, 1994, Biochem. Biophys. Res. Commnn., 198(3), 967-972). The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [125I]-[Me-Phe7]—NKB and [3H]-Senktide specific binding to NK3 receptor in equilibrium conditions (IC50). Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC50 values in the range 1-1000 nM; in particular, in guinea-pig cortex membranes by displacement of [3H]-Senktide, the compounds of the Examples 22, 47, 48, and 85 display Kis (nM) of 5.6, 8.8, 12.0 and 4.8 respectively (n=3). The NK3-antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J. Pharmacol., 101, 996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991, Eur. J. Pharmacol., 199, 9-14) and human NK3 receptors-mediated Ca++mobilization (Mochizuki et al, 1994, J. Biol. Chem, 269, 9651-9658). Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean KB value of 3-8 separate experiments, where KB is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide. Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca++ mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists. The therapeutic potential of the compounds of the present invention in treating the conditions can be assessed using rodent disease models.
  • The following Descriptions illustrate the preparation of the intermediates, whereas the Examples illustrate the preparation of the compounds of the present invention. The compounds of the Examples are summarised in the Tables 1 to 6
  • Description 1
    • 2-phenylquinoline-4-carboxylic Acid Chloride
  • 11.7 ml (136.3 mmol) of oxalyl chloride were dissolved in 150 ml of CH2Cl2. The solution was cooled at −10° C. and 20 g (80.2 mmol) of commercially available 2-phenylquinoline-4-carboxylic acid were added portionwise. The reaction mixture was left overnight at room temperature and then evaporated to dryness to yield 22 g of the title compound, used without further purification.
  • C16H10ClNO
  • M.W.=267.76
  • Description 2
    • 7-methoxy-2-phenylquinoline-4-carboxylic Acid
  • 5 g (28.2 mmol) of 6-methoxyisatin, 4 ml (33.8 mmol) of acetophenone and 5.2 g (92.6 mmol) of potassium hydroxide were dissolved in 22.9 ml of abs. EtOH and the slurry heated at 80° C. for 42 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH1 with 37% HCl and the precipitate collected by filtration and washed with water.
  • The solid obtained was dried in-vacuo at 40° C. to yield 7.0 g of the title compound.
  • C17H13NO3
  • M.P.=226-228° C.
  • M.W.=279.30
  • Elemental analysis: Calcd. C, 73.11; H, 4.69; N, 5.01; Found C, 72.07; H, 4.59; N, 4.90.
  • I.R. (KBr): 3420; 1630 cm−1.
  • Description 3
    • 7-methoxy-2-phenylquinoline-4-carboxylic Acid Chloride
  • 2.8 ml (32.3 mmol) of oxalyl chloride were dissolved in 60 ml of CH2Cl2. The solution was cooled at −10° C. and 6 g (19.0 mmol) of 7-methoxy-2-phenylquinoline-4-carboxylic acid were added portionwise. The reaction mixture was left overnight at room temperature and then evaporated to dryness to yield 7 g of the title compound, used without further purification.
  • C17H12ClNO2
  • M.W.=297.74
  • Description 4
    • 7-hydroxy-2-phenylquinoline-4-carboxylic Acid Hydroiodide
  • 1.5 g (5.4 rhmol) of 7-methoxy-2-phenylquinoline-4-carboxylic acid were added portionwise to 50 ml of 57% aqueous HI. The reaction mixture was refluxed and vigourously stirred for 5 hours; then it was evaporated in-vacuo to dryness to yield 2.1 g of the title compound.
  • C16H11NO3. HI
  • M.W.=393.17
  • I.R. (KBr): 3120; 1650; 1620 cm−1.
  • Description 5
    • 2-(2-thienyl)quinoline-4-carboxylic Acid
  • 5 g (34.0 mmol) of isatin, 4.4 ml (40.8 mmol) of 2-acetylthiophene and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40 ml of abs. EtOH and the slurry heated at 80° C. for 16 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCl and the precipitate collected by filtration and washed with water.
  • The crude product obtained was dried in-vacuo at 40° C. and triturated with EtOAc to yield 4.8 g of the title compound.
  • C14H9NO2S
  • M.P.=181-183° C.
  • M.W.=255.29
  • I.R. (KBr): 1620 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 8.60 (d, 1H); 8.45 (s, 1H); 8.10 (m, 2H); 7.78 (m, 2H); 7.68 (t, 1H); 7.22 (m, 1H).
  • Description 6
    • 2-(2-furyl)quinoline-4-carboxylic Acid
  • 5 g (34.0 mmol) of isatin, 4 ml (40.8 mmol) of 2-acetylfuran and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40.9 ml of abs. EtOH and the slurry heated at 80° C. for 12 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCl and the precipitate collected by filtration and washed with water. The crude product obtained was dried in-vacuo at 40° C. to yield 8.5 g of the title compound.
  • C14H9NO3
  • M.W.=239.23
  • Description 7
    • 2-(2-furyl)quinoline-4-carboxylic Acid Chloride
  • 5.2 ml (60.4 mmol) of oxalyl chloride were dissolved in 70 ml of CH2Cl2. The solution was cooled at −10° C. and 8.5 g (35.5 mmol) of 2-(2-furyl)quinoline-4-carboxylic acid were added portionwise. The reaction mixture was left overnight at room temperature and then evaporated to dryness to yield 9.2 g of the title compound, used without further purification.
  • C14H8ClNO2
  • M.W.=257.78
  • Description 8
    • 2-(4-pyridyl)quinoline-4-carboxylic Acid Hydrochloride
  • 5 g (34.0 mmol) of isatin, 4.5 ml (40.8 mmol) of 4-acetylpyridine and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40 ml of abs. EtOH and the slurry heated at 80° C. for 12 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCl and the precipitate collected by filtration and washed with water.
  • The aqueous solution was evaporated in-vacuo to dryness, the residue triturated with EtOH and filtered off. Evaporation of the solvent afforded 6.0 g of the crude title compound. This product was combined with the previously obtained precipitate and recrystallized from toluene containing traces of MeOH to yield 4.5 g of the title compound.
  • C15H10N2O2. HCl
  • M.P.=297-301° C.
  • M.W.=286.72
  • I.R. (KBr): 1705; 1635; 1610 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 8.90 (d, 2H); 8.70 (m, 2H); 8.50 (s, 2H); 8.28 (d, 1H); 7.89 (dt, 2H).
  • Description 9
    • 2-(4-pyridyl)quinoline-4-carboxylic Acid Chloride Hydrochloride
  • 1.3 ml (10.4 mmol) of oxalyl chloride were dissolved in 60 ml of CH2Cl2. The solution was cooled at −10° C. and 3.0 g (14.4 mmol) of 2-(4-pyridyl)quinoline-4-carboxylic acid hydrochloride were added portionwise. The reaction mixture was left 72 hours at room temperature and then evaporated to dryness to yield 4.0 g of the title compound, used without further purification.
  • C15H9ClN20 ·HCl
  • M.W.=305.22
    • EXAMPLE 1 ((R,S))—N-(α-methylbenzyl)-2-phenylquinoline-4-carboxamide
  • 1.2 ml (9.4 mmol) of ((R,S)) α-methylbenzylamine and 1.6 ml (11.7 mmol) of triethylamine (TEA) were dissolved, under nitrogen athmosphere, in 50 ml of a 1:1 mixture of dry CH2Cl2 and CH3CN.
  • 2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride, dissolved in 50 ml of a 1:4 mixture of dry CH2Cl2 and DMF, were added dropwise to the ice-cooled solution of the amines and the reaction was kept at 0°-5° C. for 1 hour and left at room temperature overnight.
  • The reaction mixture was evaporated in-vacuo to dryness, the residue was dissolved in EtOAc and washed twice with a sat. sol. of NaHCO3. The organic layer was separated, dried over Na2SO4, filtered and evaporated in-vacuo to dryness.
  • The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound as a white solid.
  • C24H20N2O
  • M.P.=156-157° C.
  • M.W.=352.43
  • Elemental analysis: Calcd. C, 81.79; H, 5.72; N, 7.95. Found C, 81.99; H, 5.69; N, 7.89.
  • I.R. (KBr): 3240;1645 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.29 (d, 1H); 8.32 (d, 2H); 8.13 (d, 1H); 8.13 (s, 1H); 8.06 (d, 1H); 7.81 (ddd, 1H); 7.68-7.52 (m, 4H); 7.47 (d, 2H); 7.39 (dd, 2H); 7.27 (dd, 1H); 5.30 (dq, 1H); 1.52 (d, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 352 (M+.); 337; 232; 204; 77.
    • EXAMPLE 2 S-(+)-N-(α-methylbenzyl)-2-phenylquinoline-4-carboxainide
  • Prepared as Ex. 1 from 1.2 ml (9.4 mmol) of S—(−)-α-methylbenzylamine, 1.6 ml (11.7 mmol) of TEA, 2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride in 100 ml of a mixture of CH2Cl2, CH3CN and DMF.
  • The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound.
  • C24H20N2O
  • M.P.=161-162° C.
  • M.W.=352.43
  • [α]D 20=+25 (C=0.5, DMF)
  • I.R. (KBr): 3240; 1645 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.29 (d, 1H); 8.32 (d, 2H); 8.13 (d, 1H); 8.13 (s, 1H); 8.06 (d, 1H); 7.81 (ddd, 1H); 7.68-7.52 (m, 4H); 7.47 (d, 2H); 7.39 (dd, 2H); 7.27 (dd, 1H); 5.30 (dq, 1H); 1.52 (d, 3H).
  • MS spactra was identical to that of the Ex. 1.
    • EXAMPLE 3 R-(−)-N-(α-methylbenzyl)-2-phenylquinoline-4-carboxamide
  • Prepared as Ex. 1 from 1.2 ml (9.4 mmol) of R—(+)-α-methylbenzylamine, 1.6 ml (11.7 mmol) of TEA and 2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride in 100 ml of a mixture of CH2Cl2, CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound.
  • C24H20N2O
  • M.P: =158-160° C.
  • M.W.=352.43
  • [α]D 20=−25 (C=0.5, DMF)
  • I.R. (KBr): 3240; 1645 cm−1.
  • The 1H-NMR and MS spectra were identical to those of the Ex. 1 and Ex. 2.
    • EXAMPLE 4 ((R,S))-N-[α-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide
  • 2.0 g (8.0 mmol) of 2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen athmosphere, in 130 ml of dry THF and 100 ml of CH3CN.
  • 2.0 g (9.9 mmol) of (D,L) methyl phenylglicinate hydrochloride and 1.5 ml (10.7 mmol) of TEA were added and the reaction mixture was cooled at 5° C.
  • 2.5 g (12.1 mmol) of dicyclohexylcarbodiimide (DCC), dissolved in 10 ml of dry CH2Cl2, were added dropwise and the solution was allowed to reach room temperature, stirred for 5 hours and left overnight.
  • The precipitated dicyclohexylurea was filtered off and the solution was evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and then washed with H2O. The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness to obtain 6.0 g of a crude product which was dissolved in 20 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness and the residue flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3:2 containing 0.5% NH4OH. The crude solid obtained was triturated with warm i—Pr2O, filtered, washed and dried to yield 1.1 g of the title compound.
  • C25H20N2O3
  • M.P.=170-172° C.
  • M.W.=396.45
  • Elemental analysis: Calcd. C, 75.74; H, 5.09; N, 7.07. Found C, 75.88; H, 5.12; N, 7.06.
  • I.R. (nujol): 3240; 1750; 1670 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.72 (d, 1H); 8.28 (dd, 2H); 8.20 (dd, 1H); 8.13 (dd, 1H); 8.11 (s, 1H); 7.83 (ddd, 1H); 7.66 (ddd, 1H); 7.60-7.50 (m, 5H); 7.47-7.37 (m, 3H); 5.78 (d, 1H); 3.72 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 396 (M+.); 337; 232; 204.
    • EXAMPLE 5 (+)-(S)-N-[α-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide
  • 2.0 g (8.0 mmol) of 2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen athmosphere, in 70 ml of dry THF and 30 ml of CH3CN.
  • 1.7 g (8.4 mmol) of (L) methyl phenylglicinate hydrochloride, 1.1 ml (9.9 mmol) of N-methylmorpholine and 2.1 g (15.5 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at 0° C.
  • 1.85 g (9.0 mmol) of DCC, dissolved in 10 ml of CH2Cl2, were added dropwise and the solution was kept at 0°-5° C. for 1 hour and then at room temperature for 2 hours. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat sol. NaHCO3, 5% citric acid, sat sol. NaHCO3 and sat. sol. NaCl.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 20 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 2.6 g of a crude product which was triturated with petroleum ether, filtered, washed with i—Pr2O and then recrystallized from 70 ml of i—PrOH to yield 1.7 g of the title compound.
  • C25H20N2O3
  • M.P.=180-181° C.
  • M.W.=396.45
  • I.R. (nujol): 3300; 1750; 1640 cm−1.
  • [α]D 20=+42.0 (C=0.5, MeOH).
  • The 1H-NMR and MS spectra were identical to those of Ex. 4.
    • EXAMPLE 6 (−)-(R)-N-[α-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide
  • Prepared as Ex. 5 from 2.0 g (8.0 mmol) of 2-phenylquinoline-4-carboxylic acid, 1.7 g (8.4 mmol) of (D) methyl phenylglicinate hydrochloride, 1.1 ml (9.9 mmol) of N-methylmorpholine, 2.1 g (15.5 mmol) of HOBT and 1.85 g (9.0 mmol) of DCC in 70 ml of dry THF and 30 ml of CH3CN.
  • The work-up of the reaction mixture was carried out in the same manner as described in Ex. 5. The crude product obtained (3.5 g) was triturated twice with warm i—Pr2O, filtered, washed and then recrystallized from 80 ml of i—PrOH to yield 2.3 g of the title compound.
  • C25H20N2O3
  • M.P.=180-181° C.
  • M.W.=396.45
  • I.R. (nujol): 3300; 1750; 1640 cm−1.
  • [α]D 20=−42.0 (C=0.5, MeOH).
  • The 1H-NMR and MS spectra were identical to those of Exs. 4 and 5.
    • EXAMPLE 7 (R,S))-N-[α-(methoxycarbonyl)benzyl]-7-methoxy-2-phenylquinoline4 carboxamide
  • 1.0 g (5.0 mmol) of (D,L) methyl phenylglicinate hydrochloride were dissolved, under nitrogen athmosphere, in 30 ml of dry DMF.
  • 2.5 g (18.1 mmol) of anhydrous potassium carbonate were added and the solution cooled at 0° C.
  • 0.7 g (2.3 mmol) of the compound of Description 3, dissolved in 25 ml of dry DMF, were added dropwise and the solution was kept at 00-5° C. for 1 hour and at room temperature overnight.
  • The reaction mixture was evaporated in-vacuo to dryness and the residue was dissolved in EtOAc and washed twice with H2O. The organic layer was separated, dried over Na2SO4, filtered and evaporated in-vacuo to dryness.
  • The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3:2 containing 0.5% NH4OH to afford 0.1 g of the crude product which was triturated with i—Pr2O to yield 0.08 g of the title compound.
  • C26H22N2O4
  • M.P.=187-190° C.
  • M.W.=426.48
  • I.R. (KBr): 3220; 1750; 1660; 1620 cm−1.
  • 300 MHz 1H-NMR (CDCl3): δ: 8.13-8.08 (m, 3H); 7.80 (s, 1H); 7.55-7.38 (m, 9H); 7.21 (dd, 1H); 7.02 (d broad, H); 5.88 (d, 1H); 3.97 (s, 3H); 3.80 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 426 (M+.); 367; 262; 234; 191;77.
    • EXAMPLE 8 ((R,S))-N-[α-(methoxycarbonyl)benzyl]-7-hydroxy-2-phenylquinoline-4-carboxamide
  • Prepared as Ex. 5 from 2.1 g (5.3 mmol) of the compound of Description 4, 1.08 g (5.3 mmol) of (D,L) methyl phenylglicinate hydrochloride, 1.5 ml (10.7 mmol) of TEA, 1.7 g (12.5 mmol) of HOBT and 1.2 g (5.8 mmol) of DCC in 70 ml of dry THF and 30 ml of CH3CN.
  • The work-up of the reaction mixture was carried out in the same manner as described in Ex. 5. The crude product obtained was triturated with i—Pr2O and then recrystallized twice from i—PrOH to yield 0.06 g of the title compound.
  • C25H20N2O4
  • M.P.=256-257° C.
  • M.W.=412.45
  • I.R. (KBr): 3270; 1750; 1650; 1620 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 10.30 (s broad, 1H); 9.64 (d, 1H); 8.22 (d, 2H); 8.04 (d, 1H); 7.85 (s, 1H); 7.60-7.34 (m, 9H); 7.21 (dd, 1H); 5.74 (d, 1H); 3.71 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 412 (M+.); 353; 248; 220; 77.
    • EXAMPLE 9 ((R,S))-N-[α-(carboxy)benzyl]-7-methoxy-2-phenylquinoline-4-carboxamide Hydrochloride
  • 0.18 g (0.4 mmol) of the product of Ex. 7 were dissolved in 10 ml of 10% HCl and 5 ml of dioxane. The reaction mixture was refluxed and stirred for 3 hours, then evaporated in-vacuo to dryness.
  • The crude product was triturated with warm EtOAc (containing a few drops of EtOH) to yield 0.16 g of the title compound.
  • C25H20N2O4·HCl
  • M.P.=228-230° C.
  • M.W.=448.91
  • I.R. (KBr): 3180; 1735; 1655; 1630 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.6 (d, 1H); 8.26 (dd, 2H); 8.14 (d, 1H); 7.98 (s, 1H); 7.63-7.52 (m, 6H); 7.46-7.36 (m, 3H); 7.33 (dd, 1H); 5.66 (d, 1H); 3.98 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 412 (M+.); 368; 262; 234; 191; 77.
    • EXAMPLE 10 ((R,S))-N-[α-(methylaminocarbonyl)benzyl]-2-phenylquinoline-4-carboxamide
  • 0.45 g (1.1 mmol) of the product of Ex. 4 were dissolved in 40 ml of 33% MeNH2/EtOH; a catalitic amount of NaCN was added and the reaction mixture was heated at 70° C. for 1 hour in a parr apparatus. The internal pressure rised to 40 psi. The solution was evaporated in-vacuo to dryness and the residue was triturated with water, filtered, dried and recrystallized from a mixture of i—PrOH (50 ml) and EtOH (30 ml) to yield 0.2 g of the title compound.
  • C25H21N3O2
  • M.P.=261-263° C.
  • M.W.=395.47
  • Elemental analysis: Calcd. C, 75.93; H, 5.35; N, 10.63. Found C, 75.65; H, 5.34; N, 10.55.
  • I.R. (KBr): 3300; 3270; 1660; 1635 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.48 (d, 1H); 8.33-8.25 (m, 3H); 8.18-8.10 (m, 3H); 7.80 (ddd, 1H); 7.68-7.50 (m, 6H); 7.40-7.28 (m, 3H); 5.75 (d, 1H); 2.63 (d, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 395 (M+.); 337; 232; 204; 77.
    • EXAMPLE 11 ((R,S))-N-[α-(methoxycarbonyl)benzyl]-2-(2-thienyl)quinoline-4-carboxamide
  • Prepared as Ex. 5 from 2.0 g (7.3 mmol) of 2-(2-thienyl)quinoline-4-carboxylic acid, 1.7 g (8.4 mmol) of (D,L) methyl phenylglicinate hydrochloride, 1.1 ml (10 mmol) of N-methylmorpholine, 2.1 g (15.5 mmol) of HOBT and 1.85 g (9.0 mmol) of DCC in 70 ml of dry THF, 30 ml of CH3CN and 10 ml of CH2Cl2.
  • The work-up of the reaction mixture was carried out in the same manner as described in Ex. 5. The crude product obtained was crystallized from EtOAc and then recrystallized from abs. EtOH to yield 0.9 g of the title compound.
  • C23H18N2O3S
  • M.P.=178-180° C.
  • M.W.=402.47
  • Elemental analysis: Calcd. C, 68.64; H, 4.51;N, 6.96. Found C, 67.50; H, 4.99; N, 7.43.
  • I.R. (KBr): 3300; 1745; 1645 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.70 (d, 1H); 8.12 (d, 1H); 8.08 (s, 1H); 8.04 (d, 1H); 8.02 (d, 1H); 7.19 (t, 1H); 7.76 (d, 1H); 7.62 (t, 1H); 7.53 (d, 2H); 7.46-7.37 (m, 3H); 7.3 (dd, 1H); 5.68 (d, 1H); 3.68 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 402 (M+.); 343; 238; 210; 77.
    • EXAMPLE 12 (R,S)-N-[α-(methoxycarbonyl)benzyl]-2-(2-furyl)quinoline-4-carboxamide
  • Prepared as Ex. 1 from 7.2 g (35.5 mmol) of (D,L) methyl phenylglicinate hydrochloride, 12.4 ml (88.8 mmol) of TEA and 9.1 g (35.5 mmol) of crude 2-(2-furyl)quinoline-4-carbonylchloride in 350 ml of a mixture of CH2Cl2, CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained was triturated with MeOH to yield 3.3 g of the title compound.
  • C23H18N2O4
  • M.P.=178-180° C.
  • M.W.=386.405
  • Elemental analysis: Calcd. C, 71.49; H, 4.70; N, 7.25. Found C, 71.67; H, 4.74; N, 7.17.
  • I.R. (KBr): 3300; 1750; 1650 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.72 (d, 1H); 8,12 (d, 1H); 8.06 (d, 1H); 7.96 (dd, 1H); 7.92 (s, 1H); 7.80 (ddd, 1H); 7.62 (ddd, 1H); 7.52 (dd, 2H); 7.45-7.35 (m, 4H); 6.73 (dd, 1H); 5.77 (d, 1H); 3.74 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 386 (M+.); 327; 222; 194; 77.
    • EXAMPLE 13 (R,S)-N-[α-(methoxycarbonyl)benzyl]-2-(4-pyridyl)quinoline-4-carboxamide
  • Prepared as Ex. 1 from 3.4 g (16.7 mmol) of (D,L) methyl phenylglicinate hydrochloride, 3.9 ml (27.8 mmol) of TEA and 3.0 g (11.1 mmol) of 2-(4-pyridyl)quinoline-4-carbonylchloride in 100 ml of a mixture of CH2Cl2, CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained was recrystallized three times from EtOAc to yield 1.9 g of the title compound.
  • C24H19N3O3
  • M.P.=172-174° C.
  • M.W.=397.43
  • Elemental analysis: Calcd. C, 72.53; H, 4.82; N, 10.57. Found C, 71.87; H, 4.87; N, 10.44.
  • I.R. (KBr): 3240; 1750; 1670 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.74 (d, 1H); 8.79 (dd, 2H); 8.27-8.17 (m, 5H); 7.89 (ddd, 1H); 7.74 (ddd, 1H); 7.54 (dd, 2H); 7.47-7.38 (m, 3H); 5.8 (d, 1H); 3.75 (s, 3H).
  • MS (EI; source 200 IC; 70 V; 200 mA): 397 (M+.); 338; 233; 205; 77.
    • EXAMPLE 14 (R,S)-N-[α-(methoxycarbonyl)-2-thienylmethyl]-2-phenylquinoline-4-carboxamide
  • Prepared as Ex. 1 from 1.94 g (9.4 mmol) of (D,L) methyl thienylglicinate hydrochloride, 2.7 ml (19.5 mmol) of TEA and 2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride in 100 ml of a mixture of CH2Cl2, CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained was recrystallized three times from EtOAc to yield 0.66 g of the title compound.
  • C23H18N2O3S
  • M.P.=144-145° C.
  • M.W.=402.47
  • Elemental analysis: Calcd. C, 68.64; H, 4.51; N, 6.96. Found C, 68.81; H, 4.46; N, 6.96.
  • I.R. (KBr): 3295; 1745; 1640 cm−1.
  • 300 MHz 1H-NMR (CDCl3): δ 8.25 (dd, 1H); 8.22 (dd, 1H); 8.17 (dd, 2H); 7.95 (s, 1H); 7.78 (ddd, 1H); 7.60 (ddd, 1H); 7.56-7.45 (m, 3H); 7.35 (dd, 1H); 7.20 (d, 1H); 7.05 (dd, 1H); 7.05 (s broad, 1H); 6.22 (d, 1H); 3.9 (s, 3H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 402 (M+.); 343; 232; 204.
    • EXAMPLE 15 (R,S)-N-[(α-(methoxycarbonylmethyl)benzyl]-2-phenylquinoline-4-carboxamide
  • Prepared as Ex. 5 from 1.39 g (5.60 mmol) of 2-phenylquinoline-4-carboxylic acid, 1.2 g (5.60 mmol) of (R,S) methyl 3-amino-3-phenylpropionate hydrochloride, 0.78 ml (5.60 mmol) of TEA, 1.51 g (11.2 mmol) of HOBT and 2.31 g (11.2 mmol) of DCC in 10 ml of dry THF, 4 ml of CH3CN and 7 ml of CH2Cl2. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 5. The crude product obtained was dissolved in CH2Cl2 and left at 0° C. overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 1.4 g of a crude product which was triturated with a mixture of i—Pr2O/acetone 99:1 to yield 1.2 g of the title compound as a white solid.
  • C26H22N2O3
  • M.P.=156-158° C.
  • M.W.=410.47
  • Elemental analysis: Calcd. C, 76.07; H, 5.40; N, 6.82. Found C, 75.77; H, 5.38; N, 6.94.
  • I.R. (KBr): 3295; 1755; 1645; 1590; 1530 cm1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.40 (d, 1H); 8.29 (dd, 2H); 8.14 (d, 1H); 8.07 (d, 1H); 8.04 (s, 1H); 7.83 (ddd, 1H); 7.66-7:52 (m, 4H); 7.50 (d, 2H); 7.40 (dd, 2H); 7.31 (ddd, 1H); 5.60 (dt, 1H); 3.65 (s, 3H); 3.04-2.89 (m, 2H).
  • MS (EI; source 200° C.; 70 V; 200 mA): 410 (M+.); 337; 233; 205.
    TABLE 1
    Figure US20050096316A1-20050505-C00015
    Molecular Melting [α]D20
    Ex. Ar R R1 R2 R3 R4 R5 * formula point ° C. c = 0.5, MeOH
    1 Ph Me H H H H Ph (R, S) C24H20N2O 156-157
    2 Ph Me H H H H Ph (S) C24H20N2O 161-162 +25°a
    3 Ph Me H H H H Ph (R) C24H20N2O 158-160 −25°a
    4 Ph COOMe H H H H Ph (R, S) C25H20N2O3 170-172
    5 Ph COOMe H H H H Ph (S) C25H20N2O3 180-181 +42°
    6 Ph COOMe H H H H Ph (R) C25H20N2O3 180-181 −42°
    7 Ph COOMe H H 7-OMe H Ph (R, S) C26H22N2O4 187-190
    8 Ph COOMe H H 7-OH H Ph (R, S) C25H20N2O4 256-257
    9 Ph COOH H H 7-OMe H Ph (R, S) C25H20N2O4.HCl 228-230
    10 Ph COONHMe H H H H Ph (R, S) C25H21N3O2 261-263
    11 Ph COOMe H H H H 2-thienyl (R, S) C23H18N2O3S 178-180
    12 Ph COOMe H H H H 2-furyl (R, S) C23H18N2O4 178-180
    13 Ph COOMe H H H H 4-Py (R, S) C24H19N3O3 172-174
    14 2-thienyl COOMe H H H H Ph (R, S) C23H18N2O3S 144-145
    15 Ph CH2COOMe H H H H Ph (R, S) C26H22N2O3 156-158

    asolvent DMF
  • TABLE 2
    The compounds of the Examples 16-9 of general formula (I) (grouped in the following Table 2) were synthesized starting from the appropriate
    acyl chlorides of (II) and amines of formula (III) shown in the table and following the synthetic procedure described in Example 1. Acyl
    chlorides were synthesized starting from the corresponding acid of formula (II) and following Description 1. Reaction yields are calculated on
    the purified, but unrecrystallized material. Analytical and spectroscopic data of the compounds of the Examples 16-49 are grouped in Table 5.
    Acyl chloride of (II) + (III) → (I)
    m.p.
    Stereo (° C.) [α]D20
    Acyl chloride chem- Molecular yield (recryst. (c = 1,
    Ex. of (II) (III) (I) istry formula M.W. (%) solv.) MeOH)
    16
    Figure US20050096316A1-20050505-C00016
    Figure US20050096316A1-20050505-C00017
    Figure US20050096316A1-20050505-C00018
         		(R) C25H22N2O3 398.47 16 120-122 (iPr2O) −18.9 (c =0.5)
    17
    Figure US20050096316A1-20050505-C00019
    Figure US20050096316A1-20050505-C00020
    Figure US20050096316A1-20050505-C00021
         		(R, S) single diast. C25H22N2O3 382.47 44 204-205 (iPrOH/ iPr2O)
    18
    Figure US20050096316A1-20050505-C00022
    Figure US20050096316A1-20050505-C00023
    Figure US20050096316A1-20050505-C00024
         		(R, S) C26H24N2O2 396.49 48 163-165 (iPrOH/ iPr2O)
    19
    Figure US20050096316A1-20050505-C00025
    Figure US20050096316A1-20050505-C00026
    Figure US20050096316A1-20050505-C00027
         		(R, S) C29H30N2O 422.58 30 147-150 (hexane)
    20
    Figure US20050096316A1-20050505-C00028
    Figure US20050096316A1-20050505-C00029
    Figure US20050096316A1-20050505-C00030
         		(R, S) C28H24N2O3 436.52 43 186-188 (iPrOH/ iPr2O)
    21
    Figure US20050096316A1-20050505-C00031
    Figure US20050096316A1-20050505-C00032
    Figure US20050096316A1-20050505-C00033
         		(R, S) C31H34N2O 450.63 24 131-134 (hexane/ iPr2O)
    22
    Figure US20050096316A1-20050505-C00034
    Figure US20050096316A1-20050505-C00035
    Figure US20050096316A1-20050505-C00036
         		(S) C26H24N2O 380.49 58 153-155 (iPr2O) −36.0
    23
    Figure US20050096316A1-20050505-C00037
    Figure US20050096316A1-20050505-C00038
    Figure US20050096316A1-20050505-C00039
         		(R) C26H24N2O 380.49 78 155-156 (iPr2O) −35.9
    24
    Figure US20050096316A1-20050505-C00040
    Figure US20050096316A1-20050505-C00041
    Figure US20050096316A1-20050505-C00042
         		(R, S) C26H22N2O4 426.48 55 124-125 (toluene)
    25
    Figure US20050096316A1-20050505-C00043
    Figure US20050096316A1-20050505-C00044
    Figure US20050096316A1-20050505-C00045
         		(R, S) C31H26N2O 442.57 49 198-200 (toluene)
    26
    Figure US20050096316A1-20050505-C00046
    Figure US20050096316A1-20050505-C00047
    Figure US20050096316A1-20050505-C00048
         		(R, S) C25H19FN2O3 414.44 75 146-147 (toluene)
    27
    Figure US20050096316A1-20050505-C00049
    Figure US20050096316A1-20050505-C00050
    Figure US20050096316A1-20050505-C00051
         		(R, S) C25H20Cl2N2O 435.36 44 193-194 (toluene)
    28
    Figure US20050096316A1-20050505-C00052
    Figure US20050096316A1-20050505-C00053
    Figure US20050096316A1-20050505-C00054
         		(R, S) C24H20N2O2 368.43 24 117-119 (toluene)
    29
    Figure US20050096316A1-20050505-C00055
    Figure US20050096316A1-20050505-C00056
    Figure US20050096316A1-20050505-C00057
         		(R, S) C25H22N2O 366.47 80 141-143 (toluene)
    30
    Figure US20050096316A1-20050505-C00058
    Figure US20050096316A1-20050505-C00059
    Figure US20050096316A1-20050505-C00060
         		(R, S) C26H22N2O3 410.48 60 180-181 (toluene/ iPr2O)
    31
    Figure US20050096316A1-20050505-C00061
    Figure US20050096316A1-20050505-C00062
    Figure US20050096316A1-20050505-C00063
         		(R, S) C26H24N2O 380.49 55 156-158 (toluene/ hexane)
    32
    Figure US20050096316A1-20050505-C00064
    Figure US20050096316A1-20050505-C00065
    Figure US20050096316A1-20050505-C00066
         		(R, S) C25H19ClN2O3 430.90 48 180-183 (toluene)
    33
    Figure US20050096316A1-20050505-C00067
    Figure US20050096316A1-20050505-C00068
    Figure US20050096316A1-20050505-C00069
         		(R, S) C26H22N2O3 410.48 48 179-181 (toluene)
    34
    Figure US20050096316A1-20050505-C00070
    Figure US20050096316A1-20050505-C00071
    Figure US20050096316A1-20050505-C00072
         		(R, S) C25H22N2O2 387.47 42 144-145 (toluene)
    35
    Figure US20050096316A1-20050505-C00073
    Figure US20050096316A1-20050505-C00074
    Figure US20050096316A1-20050505-C00075
         		(R, S) C25H19ClN2O3 430.90 46 197-199 (toluene)
    36
    Figure US20050096316A1-20050505-C00076
    Figure US20050096316A1-20050505-C00077
    Figure US20050096316A1-20050505-C00078
         		(R, S) C27H24N2O3 424.50 52 156-157 (toluene/ hexane)
    37
    Figure US20050096316A1-20050505-C00079
    Figure US20050096316A1-20050505-C00080
    Figure US20050096316A1-20050505-C00081
         		(R, S) C26H24N2O 380.49 50 149-150 (toluene)
    38
    Figure US20050096316A1-20050505-C00082
    Figure US20050096316A1-20050505-C00083
    Figure US20050096316A1-20050505-C00084
         		(R, S) C27H26N2O 394.52 53 158-159 (Et2O/ iPr2O)
    39
    Figure US20050096316A1-20050505-C00085
    Figure US20050096316A1-20050505-C00086
    Figure US20050096316A1-20050505-C00087
         		(R, S) C33H25N3O3 511.58 16 201-202 (toluene)
    40
    Figure US20050096316A1-20050505-C00088
    Figure US20050096316A1-20050505-C00089
    Figure US20050096316A1-20050505-C00090
         		(R, S) C28H28N2O 408.55 71 149-151 (toluene/ hexane)
    41
    Figure US20050096316A1-20050505-C00091
    Figure US20050096316A1-20050505-C00092
    Figure US20050096316A1-20050505-C00093
         		(S) C26H22Br2N2O 538.30 24 230-231 (Et2O/ iPr2O) −49.8 (c =0.2)
    42
    Figure US20050096316A1-20050505-C00094
    Figure US20050096316A1-20050505-C00095
    Figure US20050096316A1-20050505-C00096
         		(S) C26H23BrN2O 459.40 39 179-180 (hexane/ iPrOH) −60.5
    43
    Figure US20050096316A1-20050505-C00097
    Figure US20050096316A1-20050505-C00098
    Figure US20050096316A1-20050505-C00099
         		(R, S) C26H22N2O4 426.48 45 209-211 (Me2CO)
    44
    Figure US20050096316A1-20050505-C00100
    Figure US20050096316A1-20050505-C00101
    Figure US20050096316A1-20050505-C00102
         		(R, S) C27H20N2O4 436.47 65 240-241 (EtOAc)
    45
    Figure US20050096316A1-20050505-C00103
    Figure US20050096316A1-20050505-C00104
    Figure US20050096316A1-20050505-C00105
         		(R, S) C30H24N2O 428.53 47 194-196 (EtOAc)
    46
    Figure US20050096316A1-20050505-C00106
    Figure US20050096316A1-20050505-C00107
    Figure US20050096316A1-20050505-C00108
         		(R, S) C24H17F3N2O 406.41 45 180-181 (toluene)
    47
    Figure US20050096316A1-20050505-C00109
    Figure US20050096316A1-20050505-C00110
    Figure US20050096316A1-20050505-C00111
         		(S) C26H24N2O2 396.49 58 132-134 (Me2CO) −45 (c =0.5)
    48
    Figure US20050096316A1-20050505-C00112
    Figure US20050096316A1-20050505-C00113
    Figure US20050096316A1-20050505-C00114
         		(S) C27H26N2O 394.52 53 118-120 (hexane) −42 (c =0.5)
    49
    Figure US20050096316A1-20050505-C00115
    Figure US20050096316A1-20050505-C00116
    Figure US20050096316A1-20050505-C00117
         		(R, S) C25H21ClN2O 400.91 40 177-178 (toluene)
  • TABLE 3
    The compounds of the Examples 50-88 of general formula (I) (grouped in the following Table 3) were synthesized starting from the appropriate
    reagents (II) and (III) shown in the table and following the synthetic procedure described in Example 5. Reaction yields are calculated on the
    purified, but unrecrystallized material. Analytical and spectroscopic data of the compounds of the Examples 50-88 are grouped in Table 5.
    (II) + (III) → (I)
    m.p.
    Stereo (° C.) [α]D20
    chem- Molecular yield (recryst. (c = 1,
    Ex. (II) (III) (I) istry formula M.W. (%) solv.) MeOH)
    50
    Figure US20050096316A1-20050505-C00118
    Figure US20050096316A1-20050505-C00119
    Figure US20050096316A1-20050505-C00120
         		(R, S) C26H22N2O3 410.48 46 128-129 (iPrOH)
    51
    Figure US20050096316A1-20050505-C00121
    Figure US20050096316A1-20050505-C00122
    Figure US20050096316A1-20050505-C00123
         		(R, S) C23H18N2O3S 402.47 88 169-171 (iPrOH)
    52
    Figure US20050096316A1-20050505-C00124
    Figure US20050096316A1-20050505-C00125
    Figure US20050096316A1-20050505-C00126
         		(R, S) C27H22N2O3 422.49 41 217-219 (EtOh abs.)
    53
    Figure US20050096316A1-20050505-C00127
    Figure US20050096316A1-20050505-C00128
    Figure US20050096316A1-20050505-C00129
         		(R, S) C23H19N3O3 385.42 44 181-182 (iPrOH)
    54
    Figure US20050096316A1-20050505-C00130
    Figure US20050096316A1-20050505-C00131
    Figure US20050096316A1-20050505-C00132
         		(R, S) C22H17N3O3S 403.45 50 209-211 (iPrOH)
    55
    Figure US20050096316A1-20050505-C00133
    Figure US20050096316A1-20050505-C00134
    Figure US20050096316A1-20050505-C00135
         		(R, S) C25H20N2O 364.45 95 183-184 (iPrOH)
    56
    Figure US20050096316A1-20050505-C00136
    Figure US20050096316A1-20050505-C00137
    Figure US20050096316A1-20050505-C00138
         		(R, S) C27H26N2O 394.52 77 155-156 (iPrOH/ iPr2O)
    57
    Figure US20050096316A1-20050505-C00139
    Figure US20050096316A1-20050505-C00140
    Figure US20050096316A1-20050505-C00141
         		(R, S) C26H22N2O3 410.48 83 172-174 (iPrOH)
    58
    Figure US20050096316A1-20050505-C00142
    Figure US20050096316A1-20050505-C00143
    Figure US20050096316A1-20050505-C00144
         		(R, S) C30H32N2O 436.60 91 121-128 (iPr2O)
    59
    Figure US20050096316A1-20050505-C00145
    Figure US20050096316A1-20050505-C00146
    Figure US20050096316A1-20050505-C00147
         		(R, S) C26H22N2O3 410.48 79 180-182 (iPrOH)
    60
    Figure US20050096316A1-20050505-C00148
    Figure US20050096316A1-20050505-C00149
    Figure US20050096316A1-20050505-C00150
         		(R, S) C26H22N2O4 426.48 62 182-183 (iPrOH)
    61
    Figure US20050096316A1-20050505-C00151
    Figure US20050096316A1-20050505-C00152
    Figure US20050096316A1-20050505-C00153
         		— C27H24N2O 392.51 82 164-165 (iPrOH)
    62
    Figure US20050096316A1-20050505-C00154
    Figure US20050096316A1-20050505-C00155
    Figure US20050096316A1-20050505-C00156
         		(R, S) C25H20N2O4 412.45 50 226-227 (iPrOH)
    63
    Figure US20050096316A1-20050505-C00157
    Figure US20050096316A1-20050505-C00158
    Figure US20050096316A1-20050505-C00159
         		(R, S) C26H20N2O5 440.46 70 186-187 (iPrOH)
    64
    Figure US20050096316A1-20050505-C00160
    Figure US20050096316A1-20050505-C00161
    Figure US20050096316A1-20050505-C00162
         		— C25H22N2O 366.47 75 173-174 (iPrOH)
    65
    Figure US20050096316A1-20050505-C00163
    Figure US20050096316A1-20050505-C00164
    Figure US20050096316A1-20050505-C00165
         		(R, S) C26H24N2O 380.49 90 160-162 (iPrOH)
    66
    Figure US20050096316A1-20050505-C00166
    Figure US20050096316A1-20050505-C00167
    Figure US20050096316A1-20050505-C00168
         		(R, S) C23H19N3O3 385.42 10 202-204 (iPr2OH)
    67
    Figure US20050096316A1-20050505-C00169
    Figure US20050096316A1-20050505-C00170
    Figure US20050096316A1-20050505-C00171
         		(R, S) C25H18Cl2N2O3 465.34 59 164-165 (iPrOH)
    68
    Figure US20050096316A1-20050505-C00172
    Figure US20050096316A1-20050505-C00173
    Figure US20050096316A1-20050505-C00174
         		(R) C24H21N3O 367.45 49 139-141 (iPrOH/ iPr2O) −6.9 (c =0.5)
    69
    Figure US20050096316A1-20050505-C00175
    Figure US20050096316A1-20050505-C00176
    Figure US20050096316A1-20050505-C00177
         		(S) C25H23N3O 381.48 78 139-141 (iPrOH/ iPr2O) −68.0 (c =0.5)
    70
    Figure US20050096316A1-20050505-C00178
    Figure US20050096316A1-20050505-C00179
    Figure US20050096316A1-20050505-C00180
         		(S) C25H21ClN2O 400.91 58 137-139 (toluene/ hexane) −40.5 (c =0.5)
    71
    Figure US20050096316A1-20050505-C00181
    Figure US20050096316A1-20050505-C00182
    Figure US20050096316A1-20050505-C00183
         		(S) C25H21BrN2O 445.37 20 119-122 (toluene/ hexane) −41.4 (c =0.5)
    72
    Figure US20050096316A1-20050505-C00184
    Figure US20050096316A1-20050505-C00185
    Figure US20050096316A1-20050505-C00186
         		(R, S) C26H24N2O 380.49 59 165-166 (iPrOH)
    73
    Figure US20050096316A1-20050505-C00187
    Figure US20050096316A1-20050505-C00188
    Figure US20050096316A1-20050505-C00189
         		(S) C25H22N2O 366.46 77 140-141 (iPrOH) −26.7
    74
    Figure US20050096316A1-20050505-C00190
    Figure US20050096316A1-20050505-C00191
    Figure US20050096316A1-20050505-C00192
         		(R) C25H22N2O 366.46 51 151-152 (iPrOH) +26.6
    75
    Figure US20050096316A1-20050505-C00193
    Figure US20050096316A1-20050505-C00194
    Figure US20050096316A1-20050505-C00195
         		(R, S) C25H19FN2O3 414.44 44 174-176 (toluene/ EtOAc)
    76
    Figure US20050096316A1-20050505-C00196
    Figure US20050096316A1-20050505-C00197
    Figure US20050096316A1-20050505-C00198
         		(R, S) C25H26N2O3 402.50 53 151-153 (EtOAc)
    77
    Figure US20050096316A1-20050505-C00199
    Figure US20050096316A1-20050505-C00200
    Figure US20050096316A1-20050505-C00201
         		(R, S) C25H19ClN2O3 430.90 68 161-163 (toluene/ hexane)
    78
    Figure US20050096316A1-20050505-C00202
    Figure US20050096316A1-20050505-C00203
    Figure US20050096316A1-20050505-C00204
         		(R, S) C25H19ClN2O3 430.90 43 175-178 (toluene/ hexane)
    79
    Figure US20050096316A1-20050505-C00205
    Figure US20050096316A1-20050505-C00206
    Figure US20050096316A1-20050505-C00207
         		(R, S) C25H22N2O2 382.47 47 168-169 (toluene)
    80
    Figure US20050096316A1-20050505-C00208
    Figure US20050096316A1-20050505-C00209
    Figure US20050096316A1-20050505-C00210
         		(R, S) C27H22N2O5 454.49 16 193-194 (toluene)
    81
    Figure US20050096316A1-20050505-C00211
    Figure US20050096316A1-20050505-C00212
    Figure US20050096316A1-20050505-C00213
         		(R, S) C25H20N2O4 412.40 32 178-180 (toluene)
    82
    Figure US20050096316A1-20050505-C00214
    Figure US20050096316A1-20050505-C00215
    Figure US20050096316A1-20050505-C00216
         		(R, S) C25H18Cl2N2O3 465.34 61 142-143 (iPrOH)
    83
    Figure US20050096316A1-20050505-C00217
    Figure US20050096316A1-20050505-C00218
    Figure US20050096316A1-20050505-C00219
         		(R) C25H20N2O4.HCl 448.88 50 140 dec. (Me2CO) −7
    84
    Figure US20050096316A1-20050505-C00220
    Figure US20050096316A1-20050505-C00221
    Figure US20050096316A1-20050505-C00222
         		— C29H22N2O 414.51 42 182-184 (EtOAc)
    85
    Figure US20050096316A1-20050505-C00223
    Figure US20050096316A1-20050505-C00224
    Figure US20050096316A1-20050505-C00225
         		(S) C25H22N2O2 382.47 66 122-125 (iPr2O) −28.4 (c =0.5)
    86
    Figure US20050096316A1-20050505-C00226
    Figure US20050096316A1-20050505-C00227
    Figure US20050096316A1-20050505-C00228
         		(R) C25H22N2O2 382.47 66 122-125 (hexane/ EtOAc) +27.2 (c =0.5)
    87
    Figure US20050096316A1-20050505-C00229
    Figure US20050096316A1-20050505-C00230
    Figure US20050096316A1-20050505-C00231
         		(R) C25H20N2O4 412.45 70 125-127 (iPr2O) −50 (c =0.5)
    88
    Figure US20050096316A1-20050505-C00232
    Figure US20050096316A1-20050505-C00233
    Figure US20050096316A1-20050505-C00234
         		(R) C26H25N3O 395.51 26 133-135 (iPr2O/ iPrOH) −11.2 (c =0.5)

    (a) the phthalimido protecting group was removed by refluxing for 4h with hydrate hydrazine in 95% EtOH/1,2 dichloroethane, 9:1 respectively and then adding 37% HCl (up to pH = 1) and refluxing an additional hour.

    The compounds of the Examples 89-92 of general formula (I) (grouped in the following Table 4) were synthesized starting form other compounds of formula (I) (i.e. compounds of formula Ic) and following the synthetic procedures described in Example 10 (for compounds of the Examples 89, 90 and 91) and in Example 9 (for compound of the Example 92). Reaction yields are calculated on the purified, but unrecrystallized material. Analytical and spectroscopic data of the compounds of the Examples 89-92

    are grouped in Table 5.
  • TABLE 4
    (Ic) → (I)
    Stereo Molecular yield m.p. (° C.) [α]D20
    Ex. (Ic) (I) chemistry formula M.W. (%) (recryst. solv.) (c = 1, MeOH)
    89
    Figure US20050096316A1-20050505-C00235
    Figure US20050096316A1-20050505-C00236
         		(R, S) C26H23N3O2 409.49 22 219-221 (iPrOH/ EtOH)
    90
    Figure US20050096316A1-20050505-C00237
    Figure US20050096316A1-20050505-C00238
         		(R, S) C24H19N3O2 381.43 95 237-238 (iPrOH/ EtOH)
    91
    Figure US20050096316A1-20050505-C00239
    Figure US20050096316A1-20050505-C00240
         		(R, S) C28H25N3O2 435.53 69 199-200 (iPrOH)
    92
    Figure US20050096316A1-20050505-C00241
    Figure US20050096316A1-20050505-C00242
         		(R) C24H18N2O3.HCl 418.88 94 203-205 (acetone) −40.0 (c = 0.5)
  • TABLE 5
    Analytical and spectroscopic data of compounds of Examples 16-92
    MS (EI; source 200° C.;
    Ex. Elemental analysis IR (KBr); cm−1 70 eV; 200 μA) 300 MHz 1H NMR (DMSO), 303 K
    16 3240; 1750; 398(M+.); 232; 204 9.40(d, 1H); 8.30(d, 2H); 8.18(d, 1H); 8.13(d, 1H);
    1640; 1595; 8.10(s, 1H); 7.83(dd, 1H); 7.66(dd, 1H); 7.63-7.51(m, 3H);
    1545 5.87(s br, 1H); 5.70(m, 2H); 5.12(d, 1H); 3.80(s, 3H);
    2.92-2.60(m, 4H).
    17 Calcd. C, 78.51; H, 5.80; N, 7.32 3400; 3200; 337(M-C2H4OH)+; 9.20(d, 1H); 8.31(d, 2H); 8.14(d, 1H); 8.08(s, 1H);
    Found C, 78.27; H, 5.83; N, 7.24 1640; 1595; 232; 204 8.04(d, 1H); 7.82(dd, 1H); 7.64-7.51(m, 4H); 7.47(d, 2H);
    1532 7.37(dd, 2H); 7.27(dd, 1H); 5.10(dd, 1H); 4.81(d, 1H);
    4.13(dq, 1H); 1.18(d, 3H).
    18 Calcd. C, 78.76; H, 6.10; N, 7.07 3260; 3220; 396(M+.); 367; 262; 219 9.24(d, 1H); 8.07(d, 1H); 7.97(dd, 2H); 7.76-7.70(m, 1H);
    Found C, 78.60; H, 6.08; N, 7.00 1632; 1550* 7.62-7.51(m, 5H); 7.46(d, 2H); 7.39(dd, 2H);
    7.29(dd, 1H); 5.10(dt, 1H); 3.52(s, 3H); 1.82(dq, 2H);
    1.00(t, 3H).
    19 Calcd. C, 82.43; H, 7.16; N, 6.63 3240; 1630; 423(MH+)• (353 K): 8.89(d br, 1H); 8.00(d, 1H); 7.70(dd, 1H); 7.60-
    Found C, 82.31; H, 7.20; N, 6.58 1540 7.42(m, 9H); 7.36(dd, 2H); 7.28(dd, 1H); 5.13(dt, 1H);
    2.66(m, 2H); 1.90(ddq, 2H); 1.30(m, 2H); 1.00(t, 3H);
    0.95(m, 2H); 0.57(t br, 3H).
    20 Calcd. C, 77.04; H, 5.54; N, 6.42 3290; 1760; 436(M+.); 377; 272; 271 (353 K): 9.50(d, 1H); 8.08(d, 1H); 7.88(d, 1H); 7.80-
    Found C, 76.81; H, 5.54; N, 6.35 1645; 1590; 7.72(m, 2H); 7.60(dd, 1H); 7.52(dd, 2H); 7.47-
    1532 7.30(m, 6H); 5.90(d, 1H); 2.60(t, 2H); 2.57(t, 2H); 2.26-
    2.06(m, 2H).
    21 Calcd. C, 82.63; H, 7.61; N, 6.22 3270; 1635; 450(M+.); 421; 316 (373 K): 8.71(d br, 1H); 7.99(d, 1H); 7.70(m, 2H); 7.52-
    Found C, 82.84; H, 7.64; N, 6.16 1550* 7.42(m, 8H); 7.37(dd, 2H); 7.27(dd, 1H); 5.12(dt, 1H);
    2.67(dd, 2H); 1.91(ddq, 2H); 1.36-1.26(m, 2H); 1.12-
    1.02(m, 2H); 1.00(t, 3H); 1.00-0.90(m, 4H); 0.76(t, 3H).
    22 Calcd. C, 82.07; H, 6.36; N, 7.36 3260; 1630; 380(M+.); 351; 246; 218 (353 K): 8.90(d br, 1H); 8.01(d, 1H); 7.72(dd, 1H);
    Found C, 81.95; H, 6.33; N, 7.30 1535 7.65(d br, 1H); 7.60-7.49(m, 6H); 7.46(d, 2H); 7.38(dd, 2H);
    7.24(dd, 1H); 5.12(dt, 1H); 2.30(s, 3H); 1.98-
    1.78(m, 2H); 0.99(t, 3H).
    23 Calcd. C, 82.07; H, 6.36; N, 7.36 3260; 1630; 380(M+.); 351; 246; 218 (353 K): 8.90(d br, 1H); 8.01(d, 1H); 7.72(dd, 1H);
    Found C, 81.80; H, 6.37; N, 7.30 1535 7.65(d br, 1H); 7.60-7.49(m, 6H); 7.46(d, 2H); 7.38(dd, 2H);
    7.24(dd, 1H); 5.12(dt, 1H); 2.30(s, 3H); 1.98-
    1.78(m, 2H); 0.99(t, 3H).
    24 Calcd. C, 73.22; H, 5.20; N, 6.57 3282; 1750; 426(M+.); 367; 277 9.65(d, 1H); 8.18(d, 1H); 8.11(d, 1H); 7.96(s, 1H);
    Found C, 72.88; H, 5.25; N, 6.44 1640; 1530 7.83(dd, 1H); 7.81(dd, 1H); 7.66(dd, 1H); 7.54-7.46(m, 3H);
    7.44-7.33(m, 3H); 7.22(d, 1H); 7.13(dd, 1H);
    5.80(d, 1H); 3.87(s, 1H); 3.71(s, 3H).
    25 Calcd. C, 84.13; H, 5.92; N, 6.33 3250; 1630; 442(M+.); 413; 308; 280 8.86(d, 1H); 8.13(d, 1H); 7.83(dd, 1H); 7.71-
    Found C, 82.28; H, 5.86; N, 6.19 1545 7.59(m, 2H); 7.31-7.14(m, 12H); 7.04(d br, 2H); 4.75(dt, 1H);
    1.58-1.42(m, 2H); 0.63(t br, 3H).
    26 Calcd. C, 72.45; H, 4.62; N, 6.76 3320; 1745; 414(M+.); 355; 250; 222 9.70(d, 1H); 8.21(d, 1H); 8.16(d, 1H); 8.07(dd, 1H);
    Found C, 72.19; H, 4.66; N, 6.69 1650; 1595 7.90(d, 1H); 7.86(dd, 1H); 7.72(dd, 1H); 7.64-7.55(m, 1H);
    7.51(dd, 1H); 7.45-7.34(m, 4H); 5.80(d, 1H);
    3.75(s, 3H).
    27 Calcd. C, 69.03; H, 4.62; N, 6.44 3250; 1650; 434(M+.); 405; 232; 204 9.50(d, 1H); 8.31(d, 2H); 8.15(d, 1H); 8.10(s, 1H);
    Found C, 68.97; H, 4.63; N, 6.43 1585; 1550 8.00(d, 1H); 7.81(dd, 1H); 7.72(d, 1H); 7.66(d, 1H); 7.64-
    7.52(m, 4H); 7.46(dd, 1H); 4.11(dt, 1H); 1.83(dq, 2H);
    0.98(t, 3H).
    28 Calcd. C, 78.24; H, 5.47; N, 7.60 3260; 1645; 368(M+.); 337; 232; 204 9.22(d, 1H); 8.33(d, 2H); 8.18(s, 1H); 8.13(d, 2H);
    Found C, 78.49; H, 5.58; N, 7.41 1590; 1550 7.81(dd, 1H); 7.64-7.51(m, 4H); 7.46(d, 2H); 7.37(dd, 2H);
    7.28(dd, 1H); 5.21(dt, 1H); 5.05(t, 1H); 3.71(dd, 2H).
    29 Calcd. C, 81.93; H, 6.05; N, 7.64 3260; 1650; 366(M+.); 337; 232; 204 9.24(d, 1H); 8.30(d, 2H); 8.14(d, 1H); 8.09(s, 1H);
    Found C, 81.79; H, 6.06; N, 7.62 1595; 1550 8.02(d, 1H); 7.82(dd, 1H); 7.63-7.51(m, 4H); 7.46(d, 2H);
    7.38(dd, 2H); 7.24(dd, 1H); 5.14(dt, 1H); 1.95-
    1.78(m, 2H); 0.98(t, 3H).
    30 Calcd. C, 76.08; H, 5.40; N, 6.83 3260; 1755; 410(M+.); 351; 261; 9.70(d, 1H); 8.02(d, 1H); 7.76(dd, 1H); 7.70-
    Found C, 75.88; H, 5.37; N, 7.08 1735; 1640; 246; 217 7.47(m, 9H); 7.47-7.34(m, 3H); 6.82(d, 1H); 3.75(s, 3H);
    1580; 1530 2.32(s br, 3H).
    31 Calcd. C, 82.08; H, 6.36; N, 7.36 3220; 1630; 380(M+.); 351; 246; 217 (353 K): 9.00(d, 1H); 8.01(d, 1H); 7.37(dd, 1H); 7.60-
    Found C, 81.82; H, 6.34; N, 7.33 1550 7.48(m, 7H); 7.45(d, 2H); 7.38(dd, 2H); 7.28(dd, 1H);
    5.10(dt, 1H); 2.28(s, 3H); 2.00-1.80(m, 2H); 1.00(t, 3H).
    32 Calcd. C, 69.69; H, 4.45; N, 6.50 3270; 1750; 430(M+.); 371; 266; 238; 9.78(d, 1H); 8.29(d, 2H); 8.24(d, 1H); 8.19(d, 1H);
    Found C, 69.58; H, 4.49; N, 6.49 1670; 1595; 203 8.16(s, 1H); 7.73(dd, 1H); 7.61-7.49(m, 5H); 7.47-
    1520 7.36(m, 3H); 5.80(d, 1H); 3.79(s, 3H).
    33 Calcd. C, 76.49; H, 5.40; N, 6.82 3240; 1750; 410(M+.); 351; 246; 218 9.70(d, 1H); 8.26(d, 2H); 8.08(s, 1H); 8.03(d, 1H);
    Found C, 76.74; H, 5.40; N, 6.88 1665; 1590; 7.96(s, 1H); 7.68(dd, 1H); 7.60-7.50(m, 5H); 7.48-
    1510; 1500 7.36(m, 3H); 5.80(d, 1H); 3.79(s, 3H); 2.50(s, 3H).
    34 Calcd. C, 78.51; H, 5.79; N, 7.32, 3220; 1740; 382(M+.); 337; 232; 204 9.35(d, 1H); 8.32(d, 2H); 8.14(d, 1H); 8.11(d, 1H);
    Found C, 78.78; H, 5.78; N, 7.23 1695; 1535 8.10(s, 1H); 7.84(dd, 1H); 7.64(dd, 1H); 7.61-7.54(m, 3H);
    7.50(d, 2H); 7.40(dd, 2H); 7.30(dd, 1H); 5.41(dt, 1H);
    3.73-3.60(m, 2H); 3.36(s, 3H).
    35 Calcd. C, 69.69; H, 4.45; N, 6.50 3240; 1750; 430(M+.); 371; 266; 9.80(d, 1H); 8.29(d, 2H); 8.27(d, 1H); 8.21(s, 1H);
    Found C, 70.27; H, 4.46; N, 6.45 1670; 1590; 238; 203 8.16(d, 1H); 7.86(dd, 1H); 7.61-7.51(m, 5H); 7.48-
    1550; 1500 7.38(m, 3H); 5.80(d, 1H); 3.75(s, 3H).
    36 Calcd. C, 76.40; H, 5.70; N, 6.60 3240; 1760; 425(MH+)• (353 K): 9.52(d, 1H); 8.01(d, 1H); 7.89(s br, 1H);
    Found C, 76.44; H, 5.72; N, 6.62 1640; 1540 7.74(dd, 1H); 7.60(dd, 1H); 7.54-7.48(m, 7H); 7.44-
    7.33(m, 3H); 4.88(d, 1H); 3.78(s, 3H); 2.91-2.68(m, 2H);
    0.91(t, 3H).
    37 Calcd. C, 82.08; H, 6.36; N, 7.36 3300; 1635; 380(M+.); 337; 232; 204 9.28(d, 1H); 8.14(d, 1H); 8.07(s, 1H); 8.01(d, 1H);
    Found C, 82.21; H, 6.39; N, 7.34 1590; 1545 7.82(dd, 1H); 7.64-7.51(m, 4H); 7.46(d, 2H); 7.39(dd, 2H);
    7.28(dd, 1H); 5.15(dt, 1H); 1.94-1.69(m, 2H); 1.54-
    1.29(m, 2H); 0.95(t, 3H).
    38 Calcd. C, 82.20; H, 6.64; N, 7.10 3240; 1640; 395(MH+); CI; gas (353 K): 8.91(d, 1H); 8.00(d, 1H); 7.71(dd, 1H); 7.68-
    Found C, 82.34; H, 6.64; N, 7.07 1550 reagent methane; P 5000 7.48(m, 7H); 7.45(d, 2H); 7.39(dd, 2H); 7.29(dd, 1H);
    mTorr; source 150° C. 5.11(dt, 1H); 2.78-2.62(m, 2H); 2.00-1.80(m, 2H);
    1.00(t, 3H); 0.90(t br, 3H).
    39 Calcd. C, 77.48; H, 4.93; N, 8.21 3330; 1790; 511(M+.); 482; 377; (353 K): 8.90(d, 1H); 8.20(d, 1H); 7.94(dd, 1H); 7.88-
    Found C, 77.25; H, 4.99; N, 8.07 1720; 1665; 349; 321 6.90(m, 5H); 7.74(d, 1H); 7.69(dd, 1H); 7.48-
    1530 7.42(m, 2H); 7.36-7.31(m, 3H); 7.25-7.20(m, 2H); 7.18-
    7.10(m, 2H); 4.85(dt, 1H); 1.73(ddq, 1H); 0.82(t, 3H).
    40 Calcd. C, 82.32; H, 6.91; N, 6.86 3250; 1635; 408(M+.); 379, 289, (373 K): 8.72(d, 1H); 8.00(d, 1H); 7.70(dd, 1H); 7.55-
    Found C, 82.02; H, 6.95; N, 6.90 1550 274; 246 7.42(m, 9H); 7.38(dd, 2H); 7.28(dd, 1H); 5.15(dt, 1H);
    2.66(dd, 2H); 1.94(ddq, 2H); 1.33(m, 2H); 1.01(t, 3H);
    0.56(t, 3H).
    41 Calcd. C, 58.02; H, 4.12; N, 5.20; 3250; 1650; 537/539/541(MH+)• (353 K): 8.95(d, 1H); 7.96(d, 1H); 7.83(dd, 1H);
    Br, 29.69 1540 7.76(d, 1H); 7.71(d, 2H); 7.55(d, 2H); 7.45(dd, 2H);
    Found C, 58.14; H, 4.18; N, 5.22; 7.39(dd, 2H); 7.30(dd, 1H); 5.10(dt, 1H); 2.92(s, 3H);
    Br, 29.44 2.30(s, 3H); 1.88(ddq, 2H); 1.01(t, 3H).
    42 Calcd. C, 67.98; H, 5.04; N, 6.10; 3260; 1640; 459/461(MH+)• (353 K): 8.94(d br, 1H); 7.96(d, 1H); 7.81(dd, 1H);
    Br, 17.39 1540 7.76(d, 1H); 7.60-7.49(m, 4H); 7.45(d, 2H); 7.40(dd, 2H);
    Found C, 68.04; H, 5.02; N, 6.05; 7.30(dd, 1H); 5.10(dt, 1H); 2.30(s, 3H); 1.89(ddq, 2H);
    Br, 17.26 1.01(t, 3H).
    43 Calcd. C, 73.22; H, 5.20; N, 6.57 3200; 1750; 426(M+.); 367; 262; 234 9.70(d, 1H); 8.24(d, 2H); 8.08(s, 1H); 8.05(d, 1H);
    Found C, 73.41; H, 5.39; N, 6.61 1665; 1620; 7.61(d, 1H); 7.58-7.35(m, 9H); 5.80(d, 1H); 3.89(s, 3H);
    1520 3.74(s, 3H).
    44 Calcd. C, 74.30; H, 4.62; N, 6.42 3200; 1750; 436(M+.); 337; 272; 244 9.80(d, 1H); 8.18(d, 1H); 8.11(d, 1H); 8.09(s, 1H);
    Found C, 74.28; H, 4.61; N, 6.41 1660; 1590; 7.90(s, 1H); 7.87(dd, 1H); 7.80(d, 1H); 7.77(d, 1H);
    1550; 1525; 7.67(dd, 1H); 7.54(d, 2H); 7.47-7.31(m, 5H); 5.80(d, 1H);
    1500 3.78(s, 3H).
    45 Calcd. C, 84.08; H, 5.65; N, 6.54 3320; 1635; 337(M-C7H7)+; 232; 9.32(ABXY, 1H); 8.22(d, 2H); 8.09(d, 1H);
    Found C, 84.13; H, 5.65; N, 6.51 1590; 1530 204; 91 7.78(dd, 1H); 7.77(s, 1H); 7.64-7.52(m, 6H); 7.50-
    7.28(m, 9H); 5.53(ABXY, 1H); 3.20(ABXY, 1H);
    3.16(ABXY, 1H).
    46 Calcd. C, 70.91; H, 4.22; N, 6.89; 3300; 1655; 406(M+.); 386; 232; 204 10.15(d, 1H); 8.30(dd, 2H); 8.18(d, 1H); 8.10(s, 1H);
    F, 14.02 1590; 1540; 7.98(d, 1H); 7.86(dd, 1H); 7.75-7.42(m, 9H);
    Found C, 70.86; H, 4.17; N, 6.92; 1500 6.21(m, 1H).
    F, 13.88
    47 Calcd. C, 78.74; H, 6.10; N, 7.06 3250; 1635; 396(M+.); 367; 262; 219 9.24(d, 1H); 8.07(d, 1H); 7.97(dd, 2H); 7.76-
    Found C, 78.72; H, 6.10; N, 7.01 1550; 1500 7.70(m, 1H); 7.62-7.51(m, 5H); 7.46(d, 2H); 7.39(dd, 2H);
    7.29(dd, 1H); 5.10(dt, 1H); 3.52(s, 3H); 1.82(dq, 2H);
    1.00(t, 3H).
    48 Calcd. C, 82.18; H, 6.64; N, 7.10 3250; 1630; 394(M+.); 365; 275; 260 (353 K): 8.90(d br, 1H); 8.00(d, 1H); 7.70(dd, 1H); 7.56-
    Found C, 81.93; H, 6.64; N, 7.05 1540; 1500 7.42(m, 9H); 7.38(dd, 2H); 7.29(dd, 1H); 5.13(dt, 1H);
    2.72(m, 2H); 1.90(ddq, 2H); 1.00(t, 3H); 0.90(t br, 3H).
    49 Calcd. C, 74.90; H, 5.28; N, 6.99; 3270; 1645; 400(M+.); 371; 232; 204 9.20(d, 1H); 8.32(d, 2H); 8.08(dd, 2H); 8.06(s, 1H);
    Found C, 74.67; H, 5.33; N, 7.03; 1590; 1550; 7.82(t, 1H); 7.65-7.40(m, 8H); 5.00(dt, 1H); 1.93-
    1495; 770 1.73(m, 2H); 0.98(t, 3H).
    50 Calcd. C, 76.08; H, 5.40; N, 6.82 1750; 1640; 411(MH+); 232; 204• 8.32(d, 2H); 8.16(d, 1H); 8.10(s, 1H); 7.88(dd, 1H);
    Found C, 76.16; H, 5.42; N, 6.84 1595; 1550 7.71(dd, 1H); 7.60-7.42(m, 9H); 3.86(s, 3H); 2.56(s, 3H).
    51 Calcd. C, 68.64; H, 4.51; N, 6.96 3290; 1740; 402(M+.); 343; 238; 210 9.72(d, 1H); 8.47(dd, 1H); 8.15(d, 1H); 8.07(d, 1H);
    Found C, 68.52; H, 4.53; N, 6.94 1640; 1590; 8.05(s, 1H); 7.96(dd, 1H); 7.81(dd, 1H); 7.71(dd, 1H);
    1530 7.62(dd, 1H); 7.53(d, 2H); 7.46-7.36(m, 3H); 5.78(d, 1H);
    3.78(s, 3H).
    52 Calcd. C, 76.76; H, 5.25; N, 6.63 3250; 1750; 422(M+.); 258; 230 9.70(d, 1H); 8.45(dd, 1H); 8.18(d, 1H); 7.80-
    Found C, 76.39; H, 5.25; N, 6.55 1660; 1590; 7.38(m, 11H); 5.83(d, 1H); 3.79(s, 3H); 3.20-2.80(s br, 4H).
    1520
    53 Calcd. C, 71.68; H, 4.97; N, 10.90 3410; 3250; 385(M+.); 221; 193 11.68(s br, 1H); 9.71(d, 1H); 8.17(d, 1H); 7.99(d, 1H);
    Found C, 71.39; H, 4.99; N, 10.81 1740; 1678; 7.86(s, 1H); 7.66(dd, 1H); 7.58-7.35(m, 6H);
    1600* 7.00(sbr, 2H); 6.22(s br, 1H); 5.75(d, 1H); 3.73(s, 3H).
    54 Calcd. C, 65.50; H, 4.25; N, 10.42 3300; 1755; 344(M-COOCH3)+; 9.82(d, 1H); 8.28(s, 1H); 8.19(d, 1H); 8.14(d, 1H);
    Found C, 65.48; H, 4.22; N, 10.38 1645; 1585; 239; 211 8.10(d, 1H); 8.00(d, 1H); 7.88(dd, 1H); 7.73(dd, 1H);
    1530 7.53(d, 2H); 7.47-7.36(m, 3H); 5.80(d, 1H); 3.78(s, 3H).
    55 Calcd. C, 82.39; H, 5.53; N, 7.69 3240; 1640; 365(MH)+• 9.20(d, 1H); 8.31(d, 2H); 8.27(d, 1H); 8.16(s, 1H);
    Found C, 82.31; H, 5.52; N, 7.65 1590; 1545 8.14(d, 1H); 7.85(dd, 1H); 7.68(dd, 1H); 7.62-7-46(m, 4H);
    7.32-7.23(m, 3H); 5.69(dt, 1H); 3.08-2.85(m, 2H); 2.64-
    2.52(m, 1H); 2.10-1.96(m, 1H).
    56 Calcd. C, 82.20; H, 6.64; N, 7.10 3270; 1640; 394(M+.); 337; 232; 204 9.12(d, 1H); 8.30(d, 2H); 8.14(d, 1H); 8.07(s, 1H);
    Found C, 82.29; H, 6.66; N, 7.05 1590; 1540 8.02(d, 1H); 7.82(dd, 1H); 7.64-7.52(m, 4H); 7.46(d, 2H);
    7.39(dd, 2H); 7.28(dd, 1H); 5.13(dt, 1H); 1.96-
    1.71(m, 2H); 1.48-1.27(m, 4H); 0.9(t, 3H).
    57 Calcd. C, 76.08; H, 5.40; N, 6.82 3300; 1752; 410(M+.); 351; 246; 9.74(d, 1H); 8.20(d, 2H); 8.18(d, 1H); 8.12(d, 1H);
    Found C, 75.92; H, 5.44; N, 6.77 1642; 1590; 218; 203 8.08(s, 1H); 7.82(dd, 1H); 7.64(dd, 1H); 7.54(d, 2H); 7.47-
    1530 7.36(m, 5H); 5.8(d, 1H); 3.79(s, 3H); 2.40(s, 3H).
    58 Calcd. C, 82.53; H, 7.39; N, 6.42 3260; 1650; 337(M-C7H15)+; 249; 9.28(d, 1H); 8.29(d, 2H); 8.14(d, 1H); 8.07(s, 1H);
    Found C, 82.59; H, 7.45; N, 6.39 1590; 1550; 232; 204 8.02(d, 1H); 7.82(dd, 1H); 7.64-7.52(m, 4H); 7.46(d, 2H);
    1540 7.38(dd, 2H); 7.28(dd, 1H); 5.14(dt, 1H); 1.98-
    1.71(m, 2H); 1.30-1.20(m, 10H); 0.86(t br, 3H).
    59 Calcd. C, 76.08; H, 5.40; N, 6.82 3400-3100; 410(M+.); 261; 218 9.70(d, 1H); 8.22(d, 1H); 8.10(d, 1H); 7.84(dd, 1H);
    Found C, 76.21; H, 5.40; N, 6.79 1742; 1665; 7.70(dd, 1H); 7.67(s, 1H); 7.56(d, 1H); 7.50(dd, 2H); 7.45-
    1590; 1530 7.33(m, 5H); 5.80(d, 1H); 3.78(s, 3H); 2.42(s, 3H).
    60 Calcd. C, 73.22; H, 5.20; N, 6.57 3300; 1750; 426(M+.); 367; 262; 9.72(d, 1H); 8.25(d, 2H); 8.17(d, 1H); 8.09(d, 1H);
    Found C, 72.89; H, 5.20; N, 6.48 1645; 1590; 234; 219; 191 8.07(s, 1H); 7.80(dd, 1H); 7.62(dd, 1H); 7.54(dd, 2H); 7.46-
    1520 7.36(m, 3H); 7.12(d, 2H); 5.80(d, 1H); 3.89(s, 3H);
    3.75(s, 3H).
    61 Calcd. C, 82.62; H, 6.16; N, 7.14 3230; 1640; 392(M+.); 249; 232, 204 9.00(s, 1H); 8.32(dd, 2H); 8.13(d, 1H); 8.05(s, 1H);
    Found C, 82.76; H, 6.18; N, 7.19 1590; 1550* 7.93(d, 1H); 7.81(dd, 1H); 7.64-7.52(m, 6H); 7.39(dd, 2H);
    7.26(dd, 1H); 2.61-2.50(m, 2H); 2.10-2.00(m, 2H); 2.00-
    1.75(m, 4H).
    62 Calcd. C, 72.80; H, 4.89; N, 6.79 3500-3100; 412(M+.); 353; 248; 220 9.90(s, 1H); 9.70(d, 1H); 8.14(d, 2H): 8.14(d, 1H);
    Found C, 72.86; H, 4.91; N, 6.75 1750; 1670; 8.06(d, 1H); 8.01(s, 1H); 7.78(dd, 1H); 7.60(dd, 1H);
    1640; 1590 7.53(dd, 2H); 7.46-7.35(m, 3H); 6.94(d, 2H); 5.80(d, 3H);
    3.75(s, 3H).
    63 Calcd. C, 70.90; H, 4.58; N, 6.36 3350; 1735; 440(M+.); 381; 276; 248 9.70(d, 1H); 8.17(d, 1H); 8.09(d, 1H); 8.06(s, 1H):
    Found C, 70.73; H, 4.59; N, 6.35 1655; 1590 7.88(d, 1H); 7.85(dd, 1H); 7.80(dd, 1H); 7.62(dd, 1H);
    7.42(dd, 2H); 7.46-7.36(m, 3H); 7.10(d, 2H); 6.13(s, 2H);
    5.73(d, 1H); 3.73(s, 3H).
    64 Calcd. C, 81.94; H, 6.05; N, 7.64 3220; 1640; 366(M+.); 351; 248; 9.01(s br, 1H); 8.34(dd, 2H); 8.15(s, 1H); 8.13(d, 1H);
    Found C, 82.02; H, 6.07; N, 7.60 1590; 1545 232; 204 8.01(d, 1H); 7.81(dd, 1H); 7.66-7.52(m, 6H);
    7.39(dd, 2H); 7.25(dd, 1H).
    65 Calcd. C, 82.07; H, 6.36; N, 7.36 3320; 1640; 380(M+.); 351; 232; 204 9.20(d, 1H); 8.29(dd, 2H); 8.14(d, 1H); 8.06(s, 1H);
    Found C, 82.15; H, 6.36; N, 7.41 1590; 1530 8.03(d, 1H); 7.81(dd, 1H); 7.64-7.50(m, 4H); 7.34(d, 2H);
    7.19(d, 2H); 5.00(dt, 1H); 2.30(s, 3H); 1.93-1.73(m, 2H);
    0.98(t, 3H).
    66 Calcd. C, 71.68; H, 4.97; N, 10.90 3360; 3240; 385(M+.); 326; 221; 193 11.20(s br, 1H); 9.65(d, 1H); 8.05(d, 1H); 7.93(d, 1H);
    Found C, 70.42; H, 4.99; N, 10.56 1750; 1630; 7.78(s, 1H); 7.70(dd, 1H); 7.67(m, 1H); 7.55-
    1600; 1560 7.34(m, 6H); 6.87(m, 1H); 6.80(m, 1H); 6.77(d, 1H);
    3.75(s, 3H).
    67 Calcd. C, 64.53; H, 3.90; N, 6.02; 3200; 1755; 464(M+.); 405; 300; 9.70(d, 1H); 8.55(d, 1H); 8.30(dd, 1H); 8.22(d, 1H);
    Cl, 15.24 1635; 1590; 272; 237 8.21(s, 1H); 8.17(d, 1H); 7.86(dd, 1H); 7.84(d, 1H);
    Found C, 64.59; H, 3.95; N, 5.94; 1535 7.70(dd, 1H); 7.54(dd, 2H); 7.47-7.36(m, 3H); 5.78(d, 1H);
    Cl, 15.03 3.74(s, 3H).
    68 3300; 1635; 338; 337; 255; 233; 232; 9.18(d br, 1H); 8.35(d, 2H); 8.20(s, 1H); 8.13(d, 1H);
    1590; 1530; 204 8.07(d, 1H); 7.81(dd, 1H); 7.63-7.51(m, 4H);
    1495; 770 7.44(d, 2H); 7.38(dd, 2H); 7.28(dd, 1H); 5.08(dt br, 1H);
    2.89(d, 2H); 1.60(s br, 2H).
    69 Calcd. C, 78.71; H, 6.08; N, 11.01 3490; 3380; 381(M+.); 352; 247; 9.20(d, 1H); 7.87(m, 1H); 7.70(d, 2H); 7.59-
    Found C, 78.45; H, 6.10; N, 10.96 3260; 1630; 219; 218 7.26(m, 11H); 5.08(dt, 1H); 4.80(s br, 2H); 2.81(dq, 2H);
    1600 0.95(t, 3H).
    70 Calcd. C, 74.90; H, 5.28; N, 6.99; 3230; 1640; 400(M+.); 371; 266; 9.37(d, 1H), 8.10(d, 1H); 7.85(dd, 1H); 7.75-
    Cl, 8.84 1550 238; 203 7.35(m, 12H); 5.07(dt, 1H); 1.80(dq, 2H); 0.98(t,, 3H).
    Found C, 74.88; H, 5.25; N, 6.98;
    Cl, 8.92
    71 Calcd. C, 67.42; H, 4.75; N, 6.29; 3240; 1640; 444/446(M+.); 415/417; 9.35(d, 1H); 8.10(d, 1H); 7.85(dd br, 1H); 7.70-
    Br, 17.94 1545 310/312; 203 7.30(m, 12H); 5.05(dt, 1H); 1.81(dq, 2H); 0.99(t, 3H).
    Found C, 67.57; H, 4.80; N, 6.31;
    Br, 18.00
    72 Calcd. C, 82.07; H, 6.36; N, 7.36 3240; 381(MH)+; TSP, 9.24(d, 1H); 8.29(d, 2H); 8.14(d, 1H); 8.01(s, 1H);
    Found C, 82.00; H, 6.36; N, 7.33 1630; 1590; ammonium acetate 7.96(d, 1H); 7.81(dd, 1H); 7.64-7.51(m, 4H); 7.47-
    1545 (50 nM)/ acetonitrile 7.36(m, 4H); 7.29(dd, 1H); 4.90(dd, 1H); 2.19-
    60:40 as eluent; 2.02(m, 1H); 1.08(d, 3H); 0.80(d, 3H).
    source 250° C.
    73 Calcd. C, 81.94; H, 6.05; N, 7.64 3320; 1635; 366(M+.); 337; 232; 204 9.24(d, 1H); 8.30(d, 2H); 8.14(d, 1H); 8.09(s, 1H);
    Found C, 79.33; H, 5.82; N, 7.34 1590; 1535 8.02(d, 1H); 7.82(dd, 1H); 7.63-7.51(m, 4H); 7.46(d, 2H);
    7.38(dd, 2H); 7.24(dd, 1H); 5.14(dt, 1H); 1.95-
    1.78(m, 2H); 0.98(t, 3H).
    74 Calcd. C, 81.94; H, 6.05; N, 7.64 3280; 1637; 366(M+.); 337; 232; 204 9.24(d, 1H); 8.30(d, 2H); 8.14(d, 1H); 8.09(s, 1H);
    Found C, 82.08; H, 6.09; N, 7.59 1590; 1540 8.02(d, 1H); 7.82(dd, 1H); 7.63-7.51(m, 4H); 7.46(d, 2H);
    7.38(dd, 2H); 7.24(dd, 1H); 5.14(dt, 1H); 1.95-
    1.78(m, 2H); 0.98(t, 3H).
    75 Calcd. C, 72.45; H, 4.62; N, 6.76 3280; 1740; 414(M+.); 355; 250; 222 9.75(d, 1H); 8.28(dd, 2H); 8.21(dd, 1H); 8.2(s, 1H);
    Found C, 72.28; H, 4.59; N, 6.79 1650; 1630; 7.95(dd, 1H); 7.77(ddd, 1H); 7.61-7.50(m, 5H); 7.47-
    1550 7.36(m, 3H); 5.80(d, 1H); 3.74(s, 3H).
    76 Calcd. C, 74.60; H, 6.51; N, 6.96 1740; 1665; 402(M+.); 238; 210 9.61(d, 1H); 8.11(d, 1H); 7.99(d, 1H); 7.75(dd, 1H);
    Found C, 74.32; H, 6.50; N, 6.90 1595; 1535 7.59(dd, 1H); 7.50(d, 2H); 7.47-7.35(m, 4H); 5.74(d, 1H);
    3.72(s, 3H); 2.90(tt, 1H); 2.00-1.20(m, 10H).
    77 Calcd. C, 69.69; H, 4.45; N, 6.50 3290; 1745; 431(MH+)• 9.71(d, 1H); 8.37(s, 1H); 8.30-8.15(m, 3H);
    Found C, 69.81; H, 4.45; N, 6.54 1660; 1640; 7.85(dd, 1H); 7.69(dd, 1H); 7.63-7.38(m, 8H); 5.79(d, 1H);
    1585; 1530 3.74(s, 3H).
    78 Calcd. C, 69.69; H, 4.44; N, 6.50 3290; 1745; 431(MH+); TSP, 9.70(d, 1H); 8.24(d, 1H); 8.14(d, 1H); 7.87(dd, 1H);
    Found C, 69.90; H, 4.42; N, 6.57 1660; 1600; ammonium acetate 7.77(s, 1H); 7.76-7.62(m, 3H); 7.58-7.48(m, 4H); 7.44-
    1520 (0.1 M)/acetonitrile 7.34(m, 3H); 5.80(d, 1H); 3.72(s, 3H).
    60:40 as eluent;
    source 250° C.
    79 Calcd. C, 78.51; H, 5.80; N, 7.32 3310; 3110; 382(M+.); 353; 264; 9.80(s, 1H); 9.11(d, 1H); 8.00-7.94(m, 3H); 7.61-
    Found C, 78.55; H, 5.82; N, 7.26 1645; 1575; 247; 219 7.42(m, 8H); 7.38(dd, 2H); 7.28(dd, 1H); 5.06(dt, 1H);
    1535 1.82(ddq, 2H); 0.97(t, 3H).
    80 Calcd. C, 71.36; H, 4.88; N, 6.16 3320; 1760; 455(MH)+• 9.74(d, 1H); 8.24(dd, 2H); 8.17(s, 1H); 8.08(dd, 1H);
    Found C, 71.39; H, 4.88; N, 6.17 1735; 1650; 7.70-7.50(m, 7H); 7.46-7.35(m, 3H); 5.75(d, 1H);
    1530 3.75(s, 3H).
    81 Calcd. C, 72.80; H, 4.89; N, 6.79 3360; 3300; 413(MH)+• 9.69(d, 1H); 9.68(s, 1H); 8.49(d, 2H); 8.12(s, 1H); 7.64-
    Found C, 73.24; H, 5.00; N, 6.42 1745; 1650; 7.35(m, 10H); 7.18(d, 1H); 5.79(d, 1H); 3.77(s, 3H).
    1600; 1560;
    82 Calcd. C, 64.53; H, 3.90; N, 6.02 3240; 1740; 464(M+.); 405; 300; 10.68(d, 1H); 8.25(d, 1H); 8.14(d, 1H); 7.88(dd, 1H);
    Found C, 64.71; H, 3.96; N, 6.00 1645; 1595; 272; 237 7.82(d, 1H); 7.78(s, 1H); 7.74(dd, 1H); 7.74(d, 1H),
    1550 7.62(dd, 1H); 7.51(d, 2H); 7.44-7.33(m, 3H); 6.78(d, 1H);
    3.74(s, 3H).
    83 Calcd. C, 66.89; H, 4.72; N, 6.24; 3180; 1750; 412(M+.); 353; 232; 204 9.62(d, 1H); 8.28(d, 2H); 8.22(d, 1H); 8.16(d, 1H);
    Cl, 7.90 1660; 1645; 8.11(s, 1H); 7.86(dd, 1H); 7.68(dd, 1H); 7.61-7.51(m, 3H);
    Found C, 66.53; H, 4.74; N, 6.10; 1610; 1535; 7.30(d, 2H); 6.80(d, 2H); 5.61(d, 1H); 3.71(s, 3H).
    Cl, 7.48 1510
    84 Calcd. C, 84.03; H, 5.35; N, 6.76 3210; 1640; 414(M+.); 337; 232; 204 9.79(d, 1H); 8.30(dd, 2H); 8.15(s, 1H); 8.12(d, 1H);
    Found C, 83.27; H, 5.64; N, 7.05 1590; 1525 8.02(d, 1H); 7.81(dd, 1H); 7.63-7.26(m, 14H); 6.52(d, 1H).
    85 Calcd. C, 78.51; H, 5.80; N, 7.33 3370; 1625; 382(M+.); 264; 247; 219 9.80(s, 1H); 9.11(d, 1H); 8.00-7.94(m, 3H); 7.61-
    Found C, 78.49; H, 5.84; N, 7.26 1525 7.42(m, 8H); 7.38(dd, 2H); 7.28(dd, 1H); 5.06(dt, 1H);
    1.82(ddq, 2H); 0.97(t, 3H).
    86 Calcd. C, 78.51; H, 5.80; N, 7.33 3270; 1650; 382(M+.); 264; 247; 219 9.80(s, 1H); 9.11(d, 1H); 8.00-7.94(m, 3H); 7.61-
    Found C, 78.55; H, 5.84; N, 7.30 1630; 1570; 7.42(m, 8H); 7.38(dd, 2H); 7.28(dd, 1H); 5.06(dt, 1H);2
    1535 1.8(ddq, 2H); 0.97(t, 3H).
    87 Calcd. C, 72.80; H, 4.89; N, 6.79 3360; 1735; 412(M+.); 353; 248; 219 9.85(s, 1H); 9.63(d br, 1H); 7.97(m, 3H); 7.89(d br, 1H);
    Found C, 72.12; H, 4.88; N, 6.63 1625; 1530 7.62-7.34(m, 10H); 5.75(d, 1H); 3.76(s, 3H).
    88 Calcd. C, 78.96; H, 6.37; N, 10.62 3320; 1640; 395(M+.); 232; 204 9.15(d, 1H); 9.30(d, 2H); 9.18(dd, 2H); 8.06(s, 1H);
    Found C, 78.63; H, 6.39; N, 10.65 1590; 1525; 7.80(t, 1H); 7.70-7.20(m, 9H); 5.30(dt, 1H);
    770 2.75(dd, 1H); 2.45(dd, 1H); 2.70(s, 6H).
    89 Calcd. C, 76.26; H, 5.66; N, 10.26 3280; 1660; 409(M+.); 337; 232; 204 9.40(d, 1H); 8.26(d, 2H); 8.22(d, 1H); 8.12(d, 1H);
    Found C, 75.74; H, 5.66; N, 10.06 1635; 1590 8.05(s, 1H); 7.81(dd, 1H); 7.62(dd, 1H); 7.59-7.49(m, 5H);
    7.43-7.33(m, 3H); 6.15(d, 1H); 3.00(s, 3H); 2.90(s, 3H).
    90 Calcd. C, 75.57; H, 5.02; N, 11.02 3360; 3270; 381(M+.); 337; 232; 204 9.40(d, 1H); 8.31(d, 2H); 8.16(s, 1H); 8.15(d, 1H);
    Found C, 75.23; H, 5.12; N, 10.88 1680; 1650; 8.12(d, 1H); 7.81(dd, 1H); 7.78(s br, 1H); 7.64-7.50(m, 6H);
    1600 7.41-7.30(m, 3H); 7.23(s br, 1H); 5.71(d, 1H).
    91 Calcd. C, 77.22; H, 5.79; N, 9.65 3220; 1660; 436(MH+); TSP, 9.48(d, 1H); 8.27(d, 2H); 8.23(d, 1H); 8.12(d, 1H);
    Found C, 76.91; H, 5.87; N, 9.56 1620; 1590 ammonium acetate 8.06(s, 1H); 8.02(dd, 1H); 7.63(dd, 1H); 7.60-7.50(m, 5H);
    (0.1 M)/acetonitrile 7.45-7.33(m, 3H); 5.92(d, 1H); 3.82-3.71(m, 1H); 3.53-
    60:40 as eluent; 3.26(m, 2H); 3.16-3.08(m, 1H); 1.98-1.68(m, 4H).
    source 250° C.
    92 Calcd. C, 68.82; H, 4.57; N, 6.69; 1740; 1670; 382(M+.); 337; 204 9.64(d, 1H); 8.28(d, 2H); 8.22(d, 1H); 8.16(d, 1H);
    Cl, 8.46 1635; 1610; 8.13(s, 1H); 7.84(dd, 1H); 7.66(dd, 1H); 7.62-7.51(m, 5H);
    Found C, 68.42; H, 4.60; N, 6.56; 1540 7.46-7.34(m, 3H); 5.70(d, 1H).
    Cl, 8.22

    *oil mull;

    •FAB POS, thioglycerol matrix, Xe gas, 8 KeV, source 50° C.
    • EXAMPLE 93 (R,S)-N-[α-(Methoxycarbonyl)benzyl]-2-(p-chlorophenyl)quinoline-4-carboxamide
  • 2 g (7.0 mmol) of 2-(p-chlorophenyl)quinoline-4-carboxylic acid and 1.7 ml (15.4 mmol) of N-methylmorpholine were dissolved, under nitrogen athmosphere, in 50 ml of dry THF.
  • The solution was cooled to −20° C. and 0.91 ml (7.0 mmol) of isobutyl chloroformate were added. After 20 minutes, 2.12 g (10.5 mmol) of methyl (R,S) phenylglycinate hydrochloride and 1.3 ml (11.9 mmol) of N-methylmorpholine, dissolved in 30 ml of dry THF, were added and the reation mixture was stirred at room temperature overnight.
  • 5 ml of H2O were added and the reaction mixture was evaporated in vacuo to dryness. The residue was dissolved in Et2O, washed with a saturated solution of NaHCO3, separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/isopropyl ether 7:3 to afford 0.9 g of crude product, which was recrystallized three times with iPrO2/toluene to yield 0.5 g of the title compound.
  • C25H19ClN2O3
  • M.P.=170-172° C.
  • M.W.=430.90
  • Elemental analysis: Calcd. C, 69.72; H, 4.45; N, 6.50. Found C, 69.82; H, 4.47; N, 6.48.
  • I.R. (KBr): 3280; 1740; 1670; 1635; 1590; 1530 cm1.
  • 300 MHz 1H-NMR (DMSO-d6): 9.71 (d, 1H); 8.32 (d, 2H); 8.21 (d, 1H); 8.13 (d, 1H); 8.13 (s, 1H); 7.85 (dd, 1H); 7.67 (dd, 1H); 7.63 (d, 2H); 7.53 (dd, 2H); 7.46-7.38 (m, 3H); 5.79 (d, 1H); 3.74 (s, 3H).
  • MS (EI; source 200° C.; 70 eV; 200 μA): 430 (M+.); 371; 266; 238; 203.
    • EXAMPLE 94 (R)-N-[α-(Methoxycarbonyl)-4-methoxybenzyl]-2-phenylquinoline-4-carboxamide
  • 0.62 g (1.5 mmol) of (R)-N-[α-(methoxycarbonyl)-4-hydroxybenzyl]-2-phenylquinoline-4-carboxamide (compound of Ex. 83) were dissolved in 30 ml of dry acetone and 2 ml of dry DMF; 0.14 g (0.75 mmol) of K2CO3 were added and the reaction mixture was stirred for 30 minutes.
  • 0.093 ml (1.5 mmol) of methyl iodide were added at room temperature and the reaction mixture was heated at 40° C. for 4 hours. 0.104 g (0.75 mmol) of K2CO3 and 0.093 ml (1.5 mmol) of methyl iodide were added again, and the mixture refluxed for additional 6 hours.
  • The mixture was evaporated in vacuo to dryness, dissolved in EtOAc and washed with H2O. The organic layer, dried over Na2SO4, was evaporated in vacuo to dryness. The residue was recrystallized from Et2O to yield 0.45 g of the title compound.
  • C26H22N2O4
  • M.P.=160-162° C.
  • M.W.=426.48
  • Elemental analysis: Calcd. C, 73.22; H, 5.20; N, 6.57. Found C, 73.01; H, 5.20; N, 6.48.
  • I.R. (KBr): 3210; 1750; 1635; 1625; 1590; 1530; 1515 cm−1
  • 300 MHz 1H-NMR (DMSO-d6): 9.65 (d, 1H); 8.28 (d, 2H); 8.21 (d, 1H); 8.14 (d, 1H); 8.10 (s, 1H); 7.84 (dd, 1H); 7.67 (dd, 1H); 7.61-7.49 (m, 3H); 7.44 (d, 2H); 6.98 (d, 2H); 4.70 (d, 1H); 3.79 (s, 3H); 3.76 (s, 3H).
  • MS (EI; source 200° C.; 70 eV; 200 μA): 426 (M+.); 367; 232; 204.
    • EXAMPLE 95 (R,S)-N-[α-(Methoxycarbonyl)-α-(methyl)benzyl]-N-methyl-2-phenylquinoline-4-carboxamide hydrochloride
  • 0.50 g (1.3 mmol) of ((R,S))-N-[α-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide (compound of Ex. 4) were dissolved, under nitrogen athmosphere, in 10 ml of dry DMF.
  • The solution was cooled to 0° C. and 0.052 g (1.3 mmol) of NaH (60%) were added; after 20 minutes at 0° C. the temperature was raised to r.t. and 0.09 ml (1.4 mmol) of MeI were added. The reation mixture was stirred at room temperature overnight, then the procedure was repeated by adding additional 0.052 g (1.3 mmol) of NaH (60%) and 0.1 ml (1.6 mmol) of MeI.
  • After 6 hours at room temperature, 10 ml of saturated solution of NH4Cl were added and the reaction mixture was evaporated in vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with water; the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3:2 containing 0.5% of conc. NH4OH to afford 0.18 g of a crude product which was dissolved in Et2O and treated with HCl/Et2O to yield 0.15 g of the title compound.
  • C27H24N2O3·HCl
  • M.W.=460.96
  • I.R. (KBr): 1745; 1640; 1610 cm−1.
  • MS (EI; source 200° C.; 70 eV; 200 μA): 424 (M+.); 365; 232; 204.
    • EXAMPLE 96 (R,S)-N-[α-(Methylcarbonyl)benzyl]-2-phenylquinoline-4-carboxamide
  • 0.27 ml (3.1 mmol) of oxalyl chloride were dissolved, under nitrogen athmosphere, in 2.3 ml of dry CH2Cl2.
  • The solution was cooled to −55° C. and 0.22 ml (3.1 mmol) of DMSO, dissolved in 0.7 ml of dry CH2Cl2, were added dropwise maintaining the temperature below −50° C. The reaction was stirred at −55° C. for 7 minutes then 0.97 g (2.5 mmol) of (R,S)-N-[α-(1-hydroxyethyl)benzyl]-2-phenylquinoline-4-carboxamide (compound of Ex. 17), dissolved in 25 ml of dry CH2Cl2, were added keeping the temperature between −50 and −55° C.
  • After 30 minutes at −55° C., 1.9 ml (13.6 mmol) of TEA were added without exceeding −40° C., then the reaction mixture was allowed to reach room temperature and stirred for additional 15 minutes.
  • The reaction was quenched with 5 ml of H2O and extracted with CH2Cl2; the organic layer was washed with H2O, 20% citric acid, saturated solution of NaHCO3 and brine; the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 70:30 containing 0.5% of conc. NH4OH to afford 0.64 g of a crude product which was triturated with warm i—Pr2O/1—PrOH 2:1, filtered, washed and dried to yield 0.5 g of the title compound.
  • C25H20N2O2
  • M.P.=160-161° C.
  • M.W.=380.45
  • Elemental analysis: Calcd. C, 78.93; H, 5.30; N, 7.36. Found C, 79.01; H, 5.31; N, 7.27.
  • I.R. (KBr): 3400; 3265; 1725; 1660; 1640; 1592 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): 9.60 (d, 1H); 8.29 (d, 2H); 8.17 (d, 1H); 8.14 (d, 1H); 8.12 (s, 1H); 7.82 (dd, 1H); 7.65 (dd, 1H); 7.61-7.51 (m, 5H); 7.48-7.36 (m, 3H); 2.19 (s, 3H).
  • MS (EI; source 200° C.; 70 eV; 200 μA): 380 (M+.); 337; 232; 204.
    • EXAMPLE 97 (R,S)-N-[α-(2-Hydroxyethyl)benzyl]-2-phenylquinoline-4-carboxamide
  • 0.7 g (1.7 mmol) of ((R,S))-N-[α-(methoxycarbonylmethyl)benzyl]-2-phenylquinoline-4-carboxamide (compound of Ex. 15) were dissolved, under nitrogen athmosphere, in 50 ml of t-BuOH and 2 ml of MeOH.
  • 60 mg (1.6 mmol) of NaBH4 were added in 15 minutes to the boiling solution. The reaction mixture was refluxed for 6 hours, quenched with 5 ml of saturated solution of NH4Cl and then evaporated in vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with brine; the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • The crude product was flash chromatographed on 230-400 mesh silica gel, eluting with Et2O containing 0.5% of conc. NH4OH and then crystallized from i—PrOH to yield 0.19 g of the title compound.
  • C25H22N2O2
  • M.P.=167-169° C.
  • M.W.=382.47
  • Elemental analysis: Calcd. C, 78.52; H, 5.80; N, 7.32. Found C, 78.49; H, 5.79; N, 7.29.
  • I.R. (KBr): 3360; 1650; 1592 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): 9.30 (d, 1H); 8.31 (d, 2H); 8.13 (d, 1H); 8.10 (s, 1H); 8.03 (d, 1H); 7.81 (dd, 1H); 7.64-7.51 (m, 4H); 7.46 (d, 2H); 7.39 (dd, 2H); 7.29 (dd, 1H); 5.30 (dt, 1H); 4.61 (t, 1H); 3.61-3.41 (m, 2H); 2.11-1.86 (m, 2H).
  • MS (EI; source 200° C.; 70 eV; 200 μA): 382 (M+.); 337; 232; 204.
    • EXAMPLE 98 (S)—N-(α-Ethylbenzyl)-3(2-dimethylaminoethoxy)-2-phenylquinoline-4-carboxamide Hydrochloride
  • 0.62 g (1.6 mmol) of (S)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (compound of Ex. 85) were dissolved in 30 ml of dry DMF.
  • 0.58 g (4.0 mmol) of dimethylaminoethylchloride hydrochloride and 0.56 g (4.0 mmol) of K2CO3 were added and the reaction mixture was refluxed for 20 hours.
  • The K2CO3 was filtered off and the mixture was evaporated in vacuo to dryness, dissolved in AcOEt and washed with H2O and with 20% citric acid. The aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • The residue was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2/MeOH 98:2 containing 0.4% of conc. NH4OH and then with CH2Cl2/MeOH 86:10 containing 0.6% of conc. NH4OH to yield 85 mg of a crude product which was dissolved in EtOAc and treated with HCl/Et2O to obtain 75 mg of the title compound.
  • C29H31N3O2·HCl
  • M.P.=70° C. dec.
  • M.W.=490.05
  • I.R. (nujol): 3600; 3100; 1650; 1550 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): 10.28 (s br, 1H); 9.50 (d, 1H); 8.10 (d, 1H); 7.96 (dd, 2H); 7.78 (m, 1H); 7.67-7.61 (m, 2H); 7.61-7.51 (m, 3H); 7.49-7.39 (m, 4H); 7.33 (dd, 1H); 5.08 (dt, 1H); 3.90 (t, 2H); 2.96 (dt, 2H); 2.49 (s, 6H); 1.85 (m, 2H); 0.97 (t, 3H).
  • MS (FAB POS, thioglycerol matrix, Xe gas, 8 KeV, source 50° C.): 454 (MH+)
    • EXAMPLE 99 (S)—N-(α-Ethylbenzyl)-3-acetylamino-2-phenylquinoline-4-carboxamide
  • 0.40 g (1.05 mmol) of (S)—N-(α-ethylbenzyl)-3-amino-2-phenylquinoline-4-carboxamide (compound of Ex. 69) were heated in 25 ml of acetic anhydride at 70° C. for 1 hour and then at 100° C. for additional 3 hours.
  • The reaction mixture was then evaporated in vacuo to dryness and the residue dissolved in EtOAc; the solution was washed with water, saturated solution of NaHCO3, brine, dried over Na2SO4 and evaporated in vacuo to dryness.
  • The crude product (0.39 g) was purified by silica gel flash column chromatography, eluting with a mixture of hexane/EtOAc/conc. NH4OH, 70:30:0.5, respectively, to afford 0.2 g of a pure compound which was recrystallized from acetone to yield 0.14 g of the title compound.
  • C27H25N3O2
  • M.P.=268-269° C.
  • M.W.=423.52
  • Elemental analysis: Calcd. C, 76.57; H, 5.95; N, 9.92. Found C, 76.38; H, 5.98; N, 9.90.
  • I.R. (KBr): 3230; 1670; 1640; 1555; 1525 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): 9.65 (s, 1H); 9.05 (d, 1H); 8.10 (d, 1H); 7.80 (t, 1H); 7.70-7.50 (m, 4H); 7.45-7.20 (m, 8H); 5.08 (dt, 1H); 1.85 (m, 2H); 1.60 (s, 3H); 0.97 (t, 3H).
  • MS (EI; source 200° C.; 70 μV; 200 μA): 423 (M+.); 381; 334; 289; 261; 247; 218.
    • EXAMPLE 100 (−)-(S)-N-(α-Ethylbenzyl)-3-(3-dimethylaminopropoxy)-2-phenylquinoline-4-carboxamide Hydrochloride
  • 1.2 g (3.1 mmol) of (−)-(S)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (compound of Ex. 85) were dissolved in 15 ml of dry THF.
  • 1.0 g (8.2 mmol) of 3-dimethylaminopropylchloride, dissolved in 10 ml of Et20, 1.3 g (9.4 mmol) of K2CO3 and 0.16 g of KI were added and the reaction mixture was stirred at room temperature for 30 minutes and then refluxed for 2 hours.
  • Further 0.77 g (6.3 mmol), 1.0 g (8.2 mmol), 0.6 g (4.9 mmol) and additional 0.6 g (4.9 mmol) of 3-dimethylaminopropylchloride, dissolved each time in 10 ml of Et2O, and some KI were added every 12 hours and the reaction refluxed.
  • The K2CO3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H2O and with 20% citric acid. The aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness.
  • The residue was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2/MeOH 95:5 containing 0.5% of conc. NH4OH to yield 0.9 g of a crude product which was dissolved in EtOAc and treated with HCl/Et2O to obtain 0.62 g of the title compound.
  • C30H33N3O2·HCl
  • M.P.=108° C. dec.
  • M.W.=504.08
  • [α]D 20=−16.0 (c=0.5, MeOH)
  • I.R. (KBr): 3400; 3080; 1655; 1545 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 10.55 (s br, 1H); 9.35 (d, 1H); 8.09 (d, 1H); 7.92 (dd, 2H); 7.76 (ddd, 1H); 7.65-7.51 (m, 5H); 7.48-7.40 (m, 4H); 7.31 (dd, 1H); 5.10 (dt, 1H); 3.72-3.62 (m, 2H); 2.75-2.60 (m, 2H); 2.58 (d, 3H); 2.56 (d, 3H); 1.90-1.67 (m, 4H); 1.00 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 467 (M+.); 466; 395; 58.
    • EXAMPLE 101 (−)-(S)-N-(α-Ethylbenzyl)-3-[2-(1-phthaloyl)ethoxy]-2-phenylquinoline-4-carboxamide Hydrochloride
  • 1.9 g (5.0 mmol) of (−)-(S)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (compound of Ex. 85) were dissolved in 20 ml of dry THF.
  • 3.8 g (14.9 mmol) of 2-phthalimidoethylbromide, dissolved in 15 ml of THF, 2.0 g (14.5 mmol) of K2CO3 and 0.25 g of KI were added and the reaction mixture was stirred at room temperature for 2.5 hours and then refluxed for 2 hours.
  • 1.9 g (7.4 mmol) of 2-phthalimidoethylbromide and some KI were added and the reaction was refluxed for additional 3.5 hours.
  • 0.5 g (2.0 mmol) of 2-phthalimidoethylbromide and some KI were added again and the mixture was refluxed for 5 hours.
  • The K2CO3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in CH2Cl2 and washed with H2O. The organic layer was dried over Na2SO4 and evaporated in-vacuo to dryness.
  • The residue was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 80:20 containing 0.5% of conc. NH4OH and then hexane/EtOAc 60: 40 containing 0.5% of conc. NH4OH to afford 2.6 g of a purified product which was triturated with iPr2O to yield 2.5 g of the title compound.
  • C35H29N3O4
  • M.P.=172-175° C.
  • M.W.=555.64
  • [α]D 20=−16.3 (c=0.5, MeOH)
  • I.R. (KBr): 3280; 3060; 2960; 1780; 1715; 1660; 1530 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.27 (d, 1H); 8.03 (d, 1H); 7.92-7.84 (m, 4H); 7.78-7.69 (m, 3H); 7.60-7.53 (m, 2H); 7.46-7.38 (m, 4H); 7.27 (dd, 1H); 7.13-7.04 (m, 3H); 4.96 (dt, 1H); 3.92-3.78 (m, 2H); 3.72-3.55 (m, 2H); 1.78 (dq, 2H); 0.93 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 555 (M+.), 526, 421, 174.
    • EXAMPLE 102 (−)-(S)-N-(α-Ethylbenzyl)-3-(2-aminoethoxy)-2-phenylquinoline-4-carboxamide Hydrochloride
  • 2.2 g (3.9 mmol) of (−)-(S)—N-(α-ethylbenzyl)-3-[2-(1-phthaloyl)ethoxy]-2-phenyl quinoline-4-carboxamide hydrochloride (compound of Ex. 101) were dissolved in 150 ml of 96% EtOH and 0.38 ml (7.8 mmol) of hydrazine hydrate were added to the boiling solution, which was then refluxed for 4 hours.
  • Further 0.4 ml (8.2 mmol), 0.2 ml (4.1 mmol), 0.2 ml (4.1 mmol), 0.4 ml (8.2 mmol) and 0.4 ml (8.2 mmol) of hydrazine hydrate were added every 12 hours and the reaction mixture was maintained refluxed.
  • The reaction mixture was then evaporated in-vacuo to dryness, dissolved in 20 ml H2O, cooled and acidified with 10 ml conc. HCl.
  • The mixture was boiled for 1 hour and cooled; the phthalydrazide was filtered off. The aqueous layer was washed with EtOAc and then made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with, brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness.
  • The residue was flash chromatographed on 230-400 mesh silica gel, eluting with EtOAc/MeOH 96:4 containing 1.2% of conc. NH4OH to afford a purified product which was dissolved in EtOAc and treated with HCl/Et2O to yield 1.2 g of the title compound.
  • C27H27N3O2·HCl
  • M.P.=119° C. dec.
  • M.W.=462.00
  • [α]D 20=−19.4 (c=0.5, MeOH)
  • I.R. (KBr): 3400; 3080; 1640; 1545 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.45 (d, 1H); 8.09 (d, 1H); 8.00 (dd, 1H); 7.94 (s br, 3H); 7.76 (ddd, 1H); 7.65-7.51 (m, 4H); 7.48-7.40 (m, 3H); 7.31 (dd, 1H); 5.09 (dt, 1H); 3.83 (t, 2H); 2.72 (m, 2H); 1.93-1.80 (m, 2H); 0.99 (t, 3H).
  • MS (FAB POS, thioglycerol matrix; Xe gas, 8 keV; source 50° C.): 426 (MH+).
    • EXAMPLE 103 (+)-(S)-N-(α-Ethylbenzyl)-3-[2-(1-pyrrolidinyl)ethoxy]-2-phenylquinoline-4-carboxamide Hydrochloride
  • 2.0 g (5.2 mmol) of (−)-(S)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (compound of Ex. 85) were dissolved in 25 ml of dry THF.
  • 1.0 g (7.5 mmol) of 2-pyrrolidinoethylchloride and 2.2 g (15.9 mmol) of K2CO3 were added and the reaction mixture was stirred at room temperature for 30 minutes and then refluxed; 1.1 g (8.2 mmol) of 2-pyrrolidinoethylchloride were added to the boiling solution which was refluxed overnight.
  • The K2CO3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H2O and 20% citric acid. The aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness.
  • The residue was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2/MeOH 97:3 containing 0.5% of conc. NH4OH to yield 1.8 g of a purified product which was dissolved in EtOAc and treated with HCl/Et2O to yield 2.0 g of the title compound.
  • C31H33N3O2. HCl
  • M.P.=110-115° C. (dec.)
  • M.W.=516.08
  • [α]D 20=+4.5 (c=0.5, MeOH)
  • I.R. (KBr): 3400; 3080; 1655; 1545 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 10.50 (s br, 1H); 9.50 (d, 1H); 8.10 (d, 1H); 7.96 (dd, 2H); 7.78 (ddd, 1H); 7.68-7.30 (m, 10H); 5.10 (dt, 1H); 3.90 (m, 2H); 3.20 (m, 2H); 3.00 (m, 2H); 2.65 (m, 2H); 1.95-1.65 (m, 6H); 1.94 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 479 (M+.); 478; 383; 97; 84.
    • EXAMPLE 104 (−)-(S)-N-(α-Ethylbenzyl)-3-(dimethylaminoacetylamino)-2-phenylquinoline-4-carboxamide
  • 1.1° (2.8 mmol) of (−)-(S)—N-(α-ethylbenzyl)-3-amino-2-phenylquinoline-4-carboxamide (compound of Ex. 69) were dissolved, under nitrogen atmosphere, in 10 ml of warm toluene. 0.96 g (5.6 mmol) of chloroacetic anhydride, dissolved in 5 ml of toluene, were dropped and the solution was refluxed for 1 hour.
  • The reaction mixture was evaporated in-vacuo to dryness, suspended in 10 ml of CH2Cl2 and dropped in 5 ml of ice-cooled 28% Me2NH/EtOH.
  • The solution was stirred at room temperature overnight, then 15 ml of 28% Me2NH/EtOH were added and the reaction mixture was heated at 60° C. in a parr apparatus.
  • The mixture was evaporated in-vacuo to dryness, dissolved in 20% citric acid and washed with EtOAc. The aqueous layer was basified with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness to afford 1.4 g of the crude product.
  • This product was triturated with warm i—Pr2O to yield 0.86 g of the title compound.
  • C29H30N4O2
  • M.P.=189-191° C.
  • M.W.=466.59
  • [α]D 20=−63.1 (c=0.5, MeOH)
  • I.R. (KBr): 3230; 3180; 1670; 1630; 1540 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.41 (s, 1H); 8.97 (d, 1H), 8.08 (d, 1H); 7.81 (dd, 1H); 7.70-7.59 (m, 4H); 7.49-7.26 (m, 8H); 5.00 (dt, 1H); 2.55 (s, 2H); 1.97 (s; 3H); 1.90-1.65 (m, 2H); 0.93 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 466 (M+.); 331; 58.
    • EXAMPLE 105 N-(α,α-Dimethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
  • 2.0 g (7.5 mmol) of 3-hydroxy-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 70 ml of dry THF and 30 ml of CH3CN.
  • 1.02 g (7.5 mmol) of cumylamine and 1.12 g (8.3 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at −10° C.
  • 1.71 g (8.3 mmol) of DCC, dissolved in 20 ml of CH2Cl2, were added dropwise and the solution was kept at −5°-0° C. for 2 hours and then at room temperature overnight. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 20 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 1.4 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting initially with hexane/EtOAc 9/1 and then hexane/EtOAc 8/2 to afford 0.4 g of the purified product which was recrystallized twice from i—PrOH to yield 0.15 g of the title compound.
  • C25H22N2O2
  • M.P.=166-169° C. dec.
  • M.W.=382.47
  • I.R. (nujol): 3200; 1650; 1580; 1535 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.56 (s, 1H); 8.92 (s br, 1H); 8.00-7.94 (m, 3H); 7.76 (d br, 1H); 7.63-7.45 (m, 7H); 7.36 (dd; 2H); 7.24 (dd, 1H); 1.72 (s, 6H).
  • MS (EI; source 180 IC; 70 V; 200 mA): 382 (M+.); 264; 247; 219; 119.
    • EXAMPLE 106 N-(α,α-Dimethylbenzyl)-3-amino-2-phenylquinoline-4-carboxamide
  • 2.0 g (7.6 mmol) of 3-amino-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 70 ml of dry THF and 30 ml of CH3CN.
  • 1.02 g (7.6 mmol) of cumylamine and 1.12 g (8.3 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at −10° C.
  • 1.72 g (8.3 mmol) of DCC, dissolved in 20 ml of CH2Cl2, were added dropwise and the solution was kept at −5°-0° C. for 2 hours and then at room temperature overnight. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 20 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 2.0 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 6/4 containing 1% of conc. NH4OH to afford 0.9 g of the purified product which was recrystallized from hexane/EtOAc 1/1 and then from i—PrOH to yield 0.45 g of the title compound.
  • C25H23N3O
  • M.P.=166-168° C.
  • M.W.=381.48
  • I.R. (nujol): 3460; 3360; 3220; 1667; 1605; 1527 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.05 (s, 1H); 7.87 (dd, 1H); 7.74-7.68 (m, 3H); 7.60-7.42 (m, 7H); 7.37 (dd, 2H); 7.24 (dd, 1H); 4.74 (s, 2H); 1.71 (s, 6H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 381 (M+.); 263; 218; 119.
    • EXAMPLE 107 (−)-(S)-N-(α-Ethylbenzyl)-5-methyl-2-phenylquinoline-4-carboxamide
  • 0.80 g (3.04 mmol) of 5-methyl-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 30 ml of dry THF and 12 ml of CH3CN.
  • 0.43 g (3.20 mmol) of (S)-(−)-α-ethylbenzylamine and 0.78 g (5.78 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at −10° C.
  • 0.69 g (3.34 mmol) of DCC, dissolved in 5 ml of CH2Cl2, were added dropwise and the solution was kept at −5°-0° C. for 2 hours and then at room temperature overnight. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 10 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 1.15 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 6/2 containing 0.5% of conc. NH4OH to afford 0.47 g of the purified product which was recrystallized from i—Pr20 containing some drops of EtOAc to yield 0.36 g of the title compound as a white powder.
  • C26H24N2O
  • M.P.=189-192° C.
  • M.W.=380.49
  • [α]D 20=−3.8 (c=0.5, MeOH)
  • I.R. (KBr): 3280; 3070; 3020; 1635; 1545 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.20 (d, 1H); 8.23 (d, 2H); 7.93 (d, 1H); 7.78 (s, 1H); 7.20-7.70 (m, 10H); 5.00. (dt, 1H); 2.38 (s broad, 3H); 1.70-1.90 (m, 2H); 0.95 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 380 (M+.); 246; 218.
    • EXAMPLE 108 (R,S)-N-[α-(1-Hydroxyethyl)benzyl]-3-methyl-2-phenylquinoline-4-carboxamide
  • Prepared as described in Ex. 1, starting from 11.08 g (39.33 mmol) of crude 3-methyl-2-phenylquinoline-4-carbonylchloride, 4.87 g (32.20 mmol) of 1-phenyl-2-hydroxypropylamine and 10.33 ml (74.14 mmol) of TEA in 150 ml of a 1:1 mixture of dry CH2Cl2 and CH3CN.
  • The precipitated TEA hydrochloride was filtered off and the filtrate concentrated in-vacuo to dryness; the residue was dissolved in CH2Cl2 (100 ml) and washed with a sat. sol. of NaHCO3, 20% citric acid and brine. The organic solution was dried over Na2SO4 and evaporated in-vacuo to dryness to obtain 13.23 g of an oil, which was crystallized from i—PrO2 (100 ml) containing 6 ml of i—PrOH to yield 9.14 g of the title compound as an off-white solid.
  • C26H24N2O2
  • M.P.=163-165° C.
  • M.W.=396.49
  • I.R. (nujol): 3400; 3260; 1635; 1580 cm−1.
    • EXAMPLE 109 (R,S)-N-[α-(Methylcarbonyl)benzyl]-3-methyl-2-phenylquinoline-4-carboxamide
  • Prepared as described in Example 96, starting from 3.25 g (25.60 mmol) of oxalyl chloride, 3.88 g (49.66 mmol) of DMSO, 8.2 g (20.68 mmol) of (R,S)-N-[α-(1-hydroxyethyl)benzyl]-3-methyl-2-phenylquinoline-4-carboxamide (compound of Ex. 108) and 15.72 ml (112.76 mmol) of TEA in 230 ml of dry CH2Cl2.
  • The reaction was quenched with 40 ml of H2O and the organic layer separated and washed with 20% citric acid, sat. sol. NaHCO3 and brine. The organic solution was dried over Na2SO4 and evaporated in-vacuCo to dryness to afford 9.4 g of the crude title compound as an oil. This residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 70:30 containing 1% of conc. NH4OH to afford 7.7 g of the purified product which was crystallized from a mixture of EtOAc/hexane 1:3 respectively, to yield 6.0 g of the pure title compound.
  • C26H22N2O2
  • M.P.=156-158° C.
  • M.W.=394.48
  • I.R. (nujol): 3270; 3180; 1735; 1725; 1660; 1630; 1527; 1460 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.53 (d, 1H); 8.01 (d, 1H); 7.73 (dd, 1H); 7.62-7.35 (m, 12H); 5.97 (d, 1H); 2.30 (s br, 3H); 2.18 (s, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 394 (M+.); 352; 351; 246; 218; 217.
    • EXAMPLE 110 (R,S)-N-[α-(Ethyl)-4-pyridylmethyl]-2-phenylquinoline-4-carboxamide
  • 4.12 g (16:52 mmol) of 2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 40 ml of dry CH2Cl2 and 30 ml of THF.
  • 1.50 g (11.01 mmol) of 1-(4-pyridyl)-n-propyl amine and 2.23 g (16.52 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at 0° C.
  • 3.41 g (16.52 mmol) of DCC, dissolved in 26 ml of dry CH2Cl2, were added dropwise and the solution was kept at 0° C. for 2 hours and then stirred at room temperature for 36 hours. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in 100 ml of CH2Cl2 and washed with H2O, 10% K2CO3, 5% citric acid and brine.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 30 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 3.5 g of a crude product which was recrystallized three times from i-PrOH to yield 0.91 g of the title compound.
  • C24H21N3O
  • M.P.=218-219° C.
  • M.W.=367.45
  • I.R. (KBr): 3260; 3060; 1648; 1595; 1545; 1350 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.33 (d, 1H); 8.58 (d, 2H); 8.33 (dd, 2H); 8.15 (d, 1H); 8.14 (s, 1H); 8.03 (d, 1H); 7.82 (dd, 1H); 7.66-7.52 (m, 4H); 7.47 (d, 2H); 5.05 (dt, 1H); 1.85 (dq, 2H); 1.00 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 367 (M+.); 338; 232; 204.
    • EXAMPLE 111 (R,S)-N-[α-(Ethyl)-2-thienylmethyl]-2-phenylquinoline-4-carboxamide
  • 1.40 g (8.00 mmol) of 1-(2-thienyl)-n-propyl amine hydrochloride and 2.45 ml (17.60 mmol) of TEA were dissolved, under nitrogen atmosphere, in 50 ml of dry CH2Cl2 and 30 ml of CH3CN.
  • 2.0 g (8.00 mmol) of 2-phenylquinoline-4-carboxylic acid and 1.30 g (9.60 mmol) of N-hydroxybenzotriazole (HOBT) were added.
  • 2.48 g (12.00 mmol) of DCC, dissolved in 30 ml of dry CH2Cl2, were added dropwise and the solution was stirred at room temperature for 36 hours.
  • 50 ml of 10% HCl were added and the solution stirred for aditional 2 hours. The precipitated dicyclohexylurea was filtered off and the organic layer washed with 10% citric acid and 10% K2CO3.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness. The crude product was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/EtOAc/CH2Cl2 80:15:0.5to afford 2.0 g of a yellow oil which was crystallized from a mixture of toluene/hexane to yield 0.9 g of the pure title compound as white crystals.
  • C23H20N2OS
  • M.P.=134-137 IC
  • M.W.=372.49
  • I.R. (KBr): 3230; 3060; 1630; 1590; 1545 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6): δ 9.33 (d, 1H); 8.30 (dd, 2H); 8.15 (d, 1H); 8.13 (d, 1H); 8.08 (s, 1H); 7.84 (ddd, 1H); 7.68-7.51 (m, 4H); 7.44 (dd, 1H); 7.11 (d, 1H); 7.02 (dd, 1H); 5.33 (dt, 1H); 2.10-1.88 (m, 2H); 1.05 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 372 (M+.); 343; 232; 204.
    • EXAMPLE 112 (+)-(S)-N-(α-Ethylbenzyl)-3-dimethylaminomethyl-2-phenylquinoline-4-carboxamide hydrochloride
  • 5.60 g (21.27 mmol) of 3-methyl-2-phenylquinoline-4-carboxylic acid were dissolved in 100 ml of dichloroethane.
  • 7.60 g (42.50 mmol) of N-bromosuccinimide and 0.52 g (2.00 mmol) of dibenzoyl peroxide were added and the solution refluxed for 24 hours.
  • The reaction mixture was evaporated in-vacuo to dryness, suspended in 100 ml of 33% Me2NH/EtOH and stirred overnight at room temperature.
  • The solution was evaporated in-vacuo to dryness, dissolved in 50 ml of 20% K2CO3 and evaporated again in-vacuo to dryness. 50 ml of water were added to the residue and the solution, acidified with 37% HCl, was evaporated in-vacuo to dryness.
  • The crude residue and 10.8 ml (77.20 mmol) of TEA were dissolved in 50 ml of CH2Cl2, 50 ml of THF and 100 ml of CH3CN.
  • 3.00 g (22.20 mmol) of (S)-(−)-α-ethylbenzylamine, 0.78 g (5.78 mmol) of N-hydroxybenzotriazole (HOBT) and 11.9 g (57.90 mmol) of DCC were added and the solution was stirred at room temperature overnight.
  • The precipitated dicyclohexylurea was filtered off and the organic layer evaporated in-vacuo to dryness.
  • The brown oily residue was dissolved in 100 ml of CH2Cl2 and the precipitate was filtered off. The filtrate was extracted three times with 40% citric acid. The acqueous layer, basified with solid K2CO3, was extracted with CH2Cl2; the organic solution dried over Na2SO4 and evaporated in-vacuo to dryness afforded 10 g of a brown oil.
  • The crude product was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of i—Pr2O/CH2Cl2 9:1 to afford 2.5 g of a white solid which was dissolved in toluene and left overnight.
  • The DCU precipitated was filtered and the solution, treated with ethanolic HCl, was evaporated in-vacuo to dryness. The crude product was recrystallized from a mixture of toluene/EtOH to yield 0.7 g of the pure title compound as colourless crystals.
  • C28H29N3·OHCl
  • M.P.=164-167° C.
  • M.W.=460.02
  • [α]D 20=+25.3 (c=1, MeOH)
  • I.R. (KBr): 3440; 3150; 3020; 2560; 2460; 1650; 1540 cm−1.
  • 300 MHz 1H-NMR (DMSO-d6, 353 K): δ 9.70 (s br, 1H); 8.10 (d, 1H); 7.85 (dd, 1H); 7.80 (s br, 1H); 7.70-7.10 (m, 12H); 5.15 (dt, 1H); 4.38-4.20 (m, 2H); 2.30 (s, 3H); 2.22 (s, 6H); 2.10-1.82 (m, 2H); 1.00 (t, 3H).
  • MS (EI; source 180° C.; 70 V; 200 mA): 423 (M+.), 380, 288.
    • EXAMPLE 113 (S)—N-(α-Ethylbenzyl)-3-methyl-7-methoxy-2-phenylquinoline-4-carboxamide
  • Prepared as described in Ex. 1, starting from 1.27 g (4.09 mmol) of crude 3-methyl-7-methoxy-2-phenylquinoline-4-carbonylchloride, 0.55 g (4.09 mmol) of (S)-(−)-α-ethylbenzylamine and 1.71 ml (12.27 mmol) of TEA in 24 ml of dry CH2Cl2 and 1 ml of DMF to help solubility. The reaction mixture was stirred 12 hours at room temperture.
  • After being concentrated in-vacuo to dryness, the residue was dissolved in CH2Cl2 (30 ml) and washed with 10% NaHCO3, 5% citric acid and brine. The organic solution was dried over Na2SO4 and evaporated in-vacuo to dryness to obtain 1.87 g of a crude product, which was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/EtOAc 70:30 to afford 0.350 g of a yellow oil.
  • C27H26N2O2
  • M.W.=410.51
  • I.R. (KBr): 3240; 2965; 2930; 1635; 1535; 1220 cm−1.
    • EXAMPLE 114 (S)-N-(α-Ethylbenzyl)-3-amino-5-methyl-2-phenylquinoline-4-carboxamide
  • 0.75 g (2.64 mmol) of 3-amino-5-methyl-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 30 ml of dry THF and 10 ml of CH3CN.
  • 0.38 g (2.83 mmol) of (S)-(−)-α-ethylbenzylamine and 0.69 g (5.18 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at −10° C.
  • 0.61 g (2.97 mmol) of DCC, dissolved in 5 ml of CH2Cl2, were added dropwise and the solution was kept at −5°-0° C. for 2 hours, heated at 50° C. for 4 hours and then left at room temperature overnight.
  • The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 10 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 0.86 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2/MeOH/conc. NH4OH, 90:10:0.5 respectively, to afford 0.41 g of the title compound as an oil.
  • C26H25N3O
  • M.W.=395.50
  • I.R. (KBr): 3480; 3390; 3230; 3020; 1635; 1615; 1545 cm−1.
    • EXAMPLE 115 (S)-N-(α-Ethylbenzyl)-3-methoxy 5-methyl-2-phenylquinoline-4-carboxamide
  • 1.29 g (4.40 mmol) of 3-methoxy-5-methyl-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 40 ml of dry THF and 20 ml of CH3CN.
  • 0.63 g (4.62 mmol) of (S)-(−)-α-ethylbenzylamine and 1.13 g (8.36 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at −10° C.
  • 1.0 g (4.84 mmol) of DCC, dissolved in 5 ml of CH2Cl2, were added dropwise and the solution was kept at −5°-0° C. for 2 hours, heated at 50° C. for 4 hours and then left at room temperature overnight.
  • The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.
  • The organic layer was separated, dried over Na2SO4 and evaporated in-vacuo to dryness; the residue was dissolved in 20 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.
  • The solution was evaporated in-vacuo to dryness to obtain 2.45 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 7:2 containing 0.5% of conc. NH4OH, to afford 0.28 g of the title compound as an oil.
  • C27H26N2O2
  • M.W.=410.52
  • I.R. (KBr): 3270; 3020; 1635; 1535 cm−1.
    TABLE 6
    Analytical data of compounds of Examples 93-115.
    Figure US20050096316A1-20050505-C00243
    Molecular Melting [α]D20
    Ex. Ar R R1 R2 R3 R4 R5 * formula point ° C. c = 0.5, MeOH
    93 Ph COOMe H H H H Ph(4-Cl) (R, S) C25H19ClN2O3 170-172 —
    94 Ph(4-OMe) COOMe H H H H Ph (R) C26H22N2O4 160-162
    95 Ph COOMe Me Me H H Ph (R, S) C27H24N2O3.HCl —
    96 Ph COMe H H H H Ph (R, S) C25H20N2O2 160-161 —
    97 Ph CH2CH2OH H H H H Ph (R, S) C25H22N2O2 167-169 —
    98 Ph Et H H H OCH2CH2NMe2 Ph (S) C29H31N3O2.HCl 70 dec.a —b
    99 Ph Et H H H NHCOMe Ph (S) C27H25N3O2 268-269 −71.4
    100 Ph Et H H H OCH2CH2CH2NMe2 Ph (S) C30H33N3O2.HCl 108 dec. −16.0
    101 Ph Et H H H OCH2CH2phthalimido Ph (S) C35H29N3O4 172-175 −16.3
    102 Ph Et H H H OCH2CH2NH2 Ph (S) C27H27N3O2.HCl 119 dec. −19.4
    103 Ph Et H H H OCH2CH2pyrrolidino Ph (S) C31H33N3O2.HCl 110-115 +4.5
    104 Ph Et H H H NHCOCH2NMe2 Ph (S) C29H30N4O2 189-191 −63.1
    105 Ph Me Me H H OH Ph — C25H22N2O2 166-169 —
    106 Ph Me Me H H NH2 Ph — C25H23N3O 166-168 —
    107 Ph Et H H 5-Me H Ph (S) C26H24N2O 189-192 −3.8
    108 Ph CH(OH)Me H H H Me Ph (R, S) C26H24N2O2 163-165 —
    109 Ph COMe H H H Me Ph (R, S) C26H22N2O2 156-158 —
    110 4-Py Et H H H H Ph (R, S) C24H21N3O 218-219 —
    111 2-thienyl Et H H H H Ph (R, S) C23H20N2OS 134-137
    112 Ph Et H H H CH2NMe2 Ph (S) C28H29N3O.HCl 164-167 +25.3
    113 Ph Et H H 7-MeO Me Ph (S) C27H26N2O2 oil —
    114 Ph Et H H 5-Me NH2 Ph (S) C26H25N3O oil —
    115 Ph Et H H 5-Me OMe Ph (S) C27H26N2O2 oil —

    afree base: mp = 141-143;

    bfree base: [α]D 20 = −48.6 (c = 0.5, MeOH)

Claims (3)

1-16. (canceled)
17. A method of treating skin disorders and itch in mammals, comprising administering to a mammal in need thereof, a non-peptide NK3 antagonist, or a pharmaceutically acceptable salt thereof.
18. A compound of formula (I):
Figure US20050096316A1-20050505-C00244
in which:
Ar is an optionally substituted phenyl group, or a naphthyl or C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
R is linear or branched C1-8 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, an optionally substituted phenyl group or a phenyl C1-6 alkyl group, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxyxcarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or is a group —(CH2)p— when cyclized onto Ar, where p is 2 or 3;
R1 and R2, which may be the same or different, are independently hydrogen or C1-6 linear or branched alkyl, or together form a —(CH2)n— group in which n represents 3, 4, or 5; or R1 together with R forms a group —(CH2)q—, in which q is 2, 3, 4 or 5;
R3 and R4, which may be the same or different are independently hydrogen, C1-6 linear or branched alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C1-6 alkylamino, —O(CH2)r—NT2, in which r is 2, 3, or 4 and T is hydrogen or C1-6 alkyl or it forms with the adjacent nitrogen a group
Figure US20050096316A1-20050505-C00245
 in which V and VI are independently hydrogen or oxygen and u is 0, 1 or 2; —O(CH 2)S—OW2 in which s is 2, 3, or 4 and W is hydrogen or C1-6 alkyl; hydroxyalkyl, aminoalkyl, mono-or di-alkylaminoalkyl, acylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group —(CH2)t— when cyclized onto R5 as aryl, in which t is 1, 2, or 3;
R5 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, wherein the optional substituent is one of hydroxy, halogen, C1-6 alkoxy or C1-6 alkyl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
X is O, S, or N—C≡N, or a pharmaceutically acceptable salt or solvate thereof.
US10/999,180 1994-05-27 2004-11-29 Quinoline derivatives(2) Abandoned US20050096316A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/999,180 US20050096316A1 (en) 1994-05-27 2004-11-29 Quinoline derivatives(2)
US11/385,461 US7482458B2 (en) 1994-05-27 2006-03-21 Quinoline derivatives

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ITMI94A001099 1994-05-27
IT94MI001099A ITMI941099A1 (en) 1994-05-27 1994-05-27 KINOLINIC DERIVATIVES
ITMI950494 IT1293558B1 (en) 1995-03-14 1995-03-14 New tachykinin receptor antagonising quinoline derivs. - used for treating pulmonary disorders, CNS disorders, skin disorders, neurogenic inflammation, epilepsy and inflammatory pain,etc.
ITMI95A000494 1995-03-14
US08/450,437 US6608083B1 (en) 1994-05-27 1995-05-25 Quinoline derivatives(2)
US09/867,133 US20030236281A1 (en) 1994-05-27 2001-05-29 Quinoline derivatives(2)
US10/999,180 US20050096316A1 (en) 1994-05-27 2004-11-29 Quinoline derivatives(2)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/867,133 Continuation US20030236281A1 (en) 1994-05-27 2001-05-29 Quinoline derivatives(2)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/385,461 Continuation US7482458B2 (en) 1994-05-27 2006-03-21 Quinoline derivatives

Publications (1)

Publication Number Publication Date
US20050096316A1 true US20050096316A1 (en) 2005-05-05

Family

ID=26331143

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/450,438 Expired - Lifetime US5811553A (en) 1994-05-27 1995-05-25 Quinoline derivatives(2)
US08/450,437 Expired - Fee Related US6608083B1 (en) 1994-05-27 1995-05-25 Quinoline derivatives(2)
US09/867,133 Abandoned US20030236281A1 (en) 1994-05-27 2001-05-29 Quinoline derivatives(2)
US10/999,180 Abandoned US20050096316A1 (en) 1994-05-27 2004-11-29 Quinoline derivatives(2)
US11/385,461 Expired - Fee Related US7482458B2 (en) 1994-05-27 2006-03-21 Quinoline derivatives

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/450,438 Expired - Lifetime US5811553A (en) 1994-05-27 1995-05-25 Quinoline derivatives(2)
US08/450,437 Expired - Fee Related US6608083B1 (en) 1994-05-27 1995-05-25 Quinoline derivatives(2)
US09/867,133 Abandoned US20030236281A1 (en) 1994-05-27 2001-05-29 Quinoline derivatives(2)

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/385,461 Expired - Fee Related US7482458B2 (en) 1994-05-27 2006-03-21 Quinoline derivatives

Country Status (35)

Country Link
US (5) US5811553A (en)
EP (2) EP0940391B1 (en)
JP (5) JP3664492B2 (en)
KR (1) KR100316571B1 (en)
CN (3) CN1092642C (en)
AP (1) AP578A (en)
AR (1) AR037069A2 (en)
AT (2) ATE246677T1 (en)
AU (1) AU699319B2 (en)
BG (2) BG64004B1 (en)
BR (1) BR9507788A (en)
CA (1) CA2191352C (en)
CZ (1) CZ291476B6 (en)
DE (2) DE69531458T2 (en)
DK (1) DK0804419T3 (en)
DZ (1) DZ1889A1 (en)
ES (2) ES2227769T3 (en)
FI (2) FI115052B (en)
HK (2) HK1003884A1 (en)
HU (1) HU226535B1 (en)
IL (1) IL113844A (en)
MA (1) MA23560A1 (en)
MX (1) MX9605903A (en)
MY (1) MY129596A (en)
NO (2) NO307783B1 (en)
NZ (1) NZ287442A (en)
OA (1) OA10592A (en)
PL (2) PL186075B1 (en)
PT (2) PT940391E (en)
RO (1) RO114445B1 (en)
SA (1) SA95160290B1 (en)
SK (2) SK282721B6 (en)
TW (2) TW533199B (en)
UA (1) UA51623C2 (en)
WO (1) WO1995032948A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086799A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
US20080214605A1 (en) * 2005-09-21 2008-09-04 Astrazeneca Ab Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032948A1 (en) * 1994-05-27 1995-12-07 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives as tachykinin nk3 receptor antagonists
KR19990071597A (en) * 1995-11-24 1999-09-27 파올로 비지, 엔리꼬 카쭐라니 Quinoline derivative
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU757836B2 (en) * 1995-11-24 2003-03-06 Smithkline Beecham Spa Quinoline derivatives
JP4444375B2 (en) * 1997-03-14 2010-03-31 スミスクライン・ビーチャム・コーポレイション Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ID22876A (en) * 1997-05-23 1999-12-16 Smithkline Beecham Spa QUINOLIN-4-CARBOXAMIDE DEGREE AS RECIPIENT OF NK-2 AND NK-3 ANTAGONISTS
US20010012846A1 (en) * 1997-05-23 2001-08-09 Glardina Giuseppe Arnaldo Maria Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
EP1652840A3 (en) * 1997-09-17 2006-05-17 Smithkline Beecham Corporation (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
CO5150149A1 (en) * 1998-11-20 2002-04-29 Smithkline Beecham Spa PHARMACEUTICAL COMPOSITIONS DERIVED FROM QUINOLINA
ES2237408T3 (en) * 1999-01-25 2005-08-01 Smithkline Beecham Corporation ANTIANDROGENS AND PROCEDURES TO TREAT AN ILLNESS.
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002013825A1 (en) * 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
ES2259096T3 (en) * 2001-04-11 2006-09-16 Glaxosmithkline S.P.A. DERIVATIVES OF QUINOLINA-4-CARBOXAMIDE 3-REPLACED AS ANTAGONISTS OF THE NK-3 AND NK-2 RECEPTORS.
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
GB0228287D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (en) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
EP2213684A3 (en) 2003-12-22 2011-05-18 Glaxo Group Limited Nogo-a antibodies for the treatment of Alzheimer disease
EP1716137A1 (en) 2004-02-04 2006-11-02 Pfizer Products Incorporated Substituted quinoline compounds
WO2005094801A1 (en) * 2004-03-25 2005-10-13 Smithkline Beecham Corporation Use of an nk3 antagonist for the treatment of bipolar disorders
AR048193A1 (en) * 2004-03-30 2006-04-05 Smithkline Beecham Corp PROCEDURE FOR THE PREPARATION OF A DRY COMPOSITION BY SPRAYING THAT INCLUDES TALNETANT, PHARMACEUTICAL COMPOSITION OBTAINED ACCORDING TO SUCH PROCEDURE AND FORM OF DOSAGE THAT INCLUDES THE MENTIONED COMPOSITION
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2502902A3 (en) 2004-06-24 2013-11-20 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
GB0417560D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0417559D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
AU2006253054A1 (en) * 2005-06-03 2006-12-07 Astrazeneca Ab Quinoline derivatives as NK3 anatgonists
KR20080031871A (en) * 2005-06-23 2008-04-11 아스트라제네카 아베 Quinoline 3-sulfonate esters as nk3 receptor modulators
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1919871A4 (en) * 2005-08-02 2010-08-18 Glaxosmithkline Llc Method for the synthesis of quinoli e derivatives
EP1915362A1 (en) * 2005-08-11 2008-04-30 AstraZeneca AB Amide alkyl pyridiyl quinolines as nk3 receptor modulators
WO2007018469A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Oxopyridyl quinoline amides as nk3 receptor modulators
AR058051A1 (en) * 2005-09-21 2008-01-23 Astrazeneca Ab ALQUILNITRILO QUINOLINAS. OBTAINING PROCESS AND PHARMACEUTICAL COMPOSITIONS.
JP2009508944A (en) * 2005-09-21 2009-03-05 アストラゼネカ・アクチエボラーグ N-oxoheterocycles and N-oxo-alkylquinoline-4-carboxamides as NK-3 receptor ligands
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
SI3219705T1 (en) 2005-12-28 2020-08-31 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
CA2680761A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
AU2008288898B2 (en) * 2007-08-22 2014-08-07 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
WO2009049791A2 (en) * 2007-10-15 2009-04-23 F. Hoffmann-La Roche Ag Radiolabeled nk3 receptor antagonist
PE20091036A1 (en) 2007-11-30 2009-08-15 Astrazeneca Ab QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR
MX2010013868A (en) 2008-06-23 2011-02-24 Lundbeck & Co As H Isoquinolinone derivatives as nk3 antagonists.
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
KR20110070985A (en) 2008-10-20 2011-06-27 하. 룬드벡 아크티에셀스카브 Isoquinolinone derivatives as nk3 antagonists
PL2821400T3 (en) 2009-03-20 2018-04-30 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9346814B2 (en) 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN102702099A (en) * 2012-06-21 2012-10-03 江苏恩华药业股份有限公司 Preparation method of (S)-3-hydroxy-2-phenyl-N-(1-phenylpropyl) quinoline-4-formamide
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EP3160469B1 (en) 2014-06-25 2021-04-28 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
CN107074773A (en) 2014-09-09 2017-08-18 拜耳制药股份公司 Substituted N, the formamide of 2 biaryl quinolin 4 and application thereof
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JP2018512404A (en) 2015-03-18 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト Substituted N-bicyclo-2-aryl-quinoline-4-carboxamide and uses thereof
PT3297631T (en) * 2015-05-18 2019-10-10 Nerre Therapeutics Ltd Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153235A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-3-aryl-1-naphthamides and use thereof
WO2017153231A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof
WO2017153234A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof
CN105884626B (en) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 A kind of synthetic method of 2 aminoidan derivatives and products thereof
TWI770157B (en) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
KR20190138824A (en) * 2017-04-10 2019-12-16 바이엘 악티엔게젤샤프트 Substituted N-arylethyl-2-arylquinoline-4-carboxamides and uses thereof
WO2019090001A1 (en) 2017-11-02 2019-05-09 California Institute Of Technology Neurokinin antagonists and uses thereof
EP3881843A4 (en) * 2018-11-15 2022-08-03 Kyushu University, National University Corporation Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160844A (en) * 1976-05-21 1979-07-10 Fisons Limited Composition for treating skin mast cells and/or delayed cellular hypersensitivity reactions
US4711890A (en) * 1982-12-24 1987-12-08 Rhone-Poulenc Sante Pharmaceutical compositions containing azanaphthalene-carboxamide derivatives, azanaphthalene-carboxamide derivatives and process for their use
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5071987A (en) * 1989-02-22 1991-12-10 Basf Aktiengesellschaft Quinoline-4-carboxylic acid derivatives
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
US5811553A (en) * 1994-05-27 1998-09-22 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives(2)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449565B1 (en) * 1990-03-26 1997-05-14 Matsushita Electric Industrial Co., Ltd. Photosensitive material for electrophotography
ATE161530T1 (en) * 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160844A (en) * 1976-05-21 1979-07-10 Fisons Limited Composition for treating skin mast cells and/or delayed cellular hypersensitivity reactions
US4269853A (en) * 1976-05-21 1981-05-26 Fisons Limited Composition and method for treating skin mast cells and/or delayed cellular hypersensitivity reactions
US4711890A (en) * 1982-12-24 1987-12-08 Rhone-Poulenc Sante Pharmaceutical compositions containing azanaphthalene-carboxamide derivatives, azanaphthalene-carboxamide derivatives and process for their use
US5071987A (en) * 1989-02-22 1991-12-10 Basf Aktiengesellschaft Quinoline-4-carboxylic acid derivatives
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
US5811553A (en) * 1994-05-27 1998-09-22 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives(2)
US6608083B1 (en) * 1994-05-27 2003-08-19 Smithkline Beecham Farmaceutici S.P.A Quinoline derivatives(2)
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214605A1 (en) * 2005-09-21 2008-09-04 Astrazeneca Ab Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands
US7964733B2 (en) 2005-09-21 2011-06-21 Astrazeneca Ab Alkyl sulfoxide quinolines as NK-3 receptor ligands
WO2007086799A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
US20090054445A1 (en) * 2006-01-27 2009-02-26 Astrazeneca Ab Amide Substituted Quinolines
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases

Also Published As

Publication number Publication date
SK282721B6 (en) 2002-11-06
FI990268A0 (en) 1999-02-10
NO326714B1 (en) 2009-02-02
IL113844A (en) 2005-05-17
MX9605903A (en) 1998-08-30
TW427977B (en) 2001-04-01
SK151496A3 (en) 1997-07-09
JP2000026314A (en) 2000-01-25
JP2005068155A (en) 2005-03-17
ES2227769T3 (en) 2005-04-01
JP3664492B2 (en) 2005-06-29
CZ347096A3 (en) 1997-10-15
MA23560A1 (en) 1995-12-31
DE69531458T2 (en) 2004-08-05
JP2002179594A (en) 2002-06-26
CA2191352A1 (en) 1995-12-07
NO307783B1 (en) 2000-05-29
DK0804419T3 (en) 2003-11-24
EP0940391A2 (en) 1999-09-08
MY129596A (en) 2007-04-30
TW533199B (en) 2003-05-21
AU2616495A (en) 1995-12-21
CN1092642C (en) 2002-10-16
UA51623C2 (en) 2002-12-16
RO114445B1 (en) 1999-04-30
AP578A (en) 1997-03-26
NO965036L (en) 1997-01-24
BG103181A (en) 1999-09-30
SA95160290A (en) 2005-12-03
PL317381A1 (en) 1997-04-01
HUT76286A (en) 1997-07-28
IL113844A0 (en) 1995-08-31
HU9603262D0 (en) 1997-01-28
OA10592A (en) 2002-08-27
ES2204952T3 (en) 2004-05-01
EP0804419A1 (en) 1997-11-05
BR9507788A (en) 1997-09-23
CZ291476B6 (en) 2003-03-12
US20030236281A1 (en) 2003-12-25
AR037069A2 (en) 2004-10-20
SK282722B6 (en) 2002-11-06
NZ287442A (en) 1998-05-27
AP9500745A0 (en) 1995-07-31
FI964712A (en) 1997-01-23
US6608083B1 (en) 2003-08-19
JP2007126475A (en) 2007-05-24
FI115052B (en) 2005-02-28
JPH10500697A (en) 1998-01-20
BG101008A (en) 1997-08-29
SA95160290B1 (en) 2006-06-21
EP0940391B1 (en) 2004-08-18
CA2191352C (en) 2001-01-30
EP0804419B1 (en) 2003-08-06
ATE273959T1 (en) 2004-09-15
ATE246677T1 (en) 2003-08-15
EP0940391A3 (en) 1999-11-10
AU699319B2 (en) 1998-12-03
BG64004B1 (en) 2003-09-30
HK1003884A1 (en) 1998-11-13
PL186665B1 (en) 2004-02-27
DZ1889A1 (en) 2002-02-17
WO1995032948A1 (en) 1995-12-07
HU226535B1 (en) 2009-03-30
DE69533408T2 (en) 2005-09-08
NO991813L (en) 1997-01-24
SK4799A3 (en) 1999-06-11
KR100316571B1 (en) 2002-05-30
US20060160846A1 (en) 2006-07-20
CN1276211A (en) 2000-12-13
CN1156451A (en) 1997-08-06
PT804419E (en) 2003-12-31
CN1428145A (en) 2003-07-09
FI119721B (en) 2009-02-27
PL186075B1 (en) 2003-10-31
PT940391E (en) 2004-12-31
US7482458B2 (en) 2009-01-27
FI990268A (en) 1999-02-10
HK1024469A1 (en) 2000-10-13
NO965036D0 (en) 1996-11-26
US5811553A (en) 1998-09-22
DE69533408D1 (en) 2004-09-23
DE69531458D1 (en) 2003-09-11
FI964712A0 (en) 1996-11-26
NO991813D0 (en) 1999-04-16

Similar Documents

Publication Publication Date Title
US7482458B2 (en) Quinoline derivatives
US6743804B2 (en) Quinoline derivatives as NK3 antagonists
US6277862B1 (en) Quinoline derivatives
WO1996002509A1 (en) Quinoline derivatives as nk3 antagonists
US6355654B1 (en) Salts of quinoline derivatives as NK3 antagonists
RU2155754C2 (en) Quinoline derivatives as techychinin nk3 receptor antagonists
CA2257662C (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
AU757836B2 (en) Quinoline derivatives
AU4263200A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
PL188872B1 (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
AU5784501A (en) Quinoline derivatives as tachykinin NK3 receptor antagonists

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION